- freely available
Cancers 2014, 6(1), 240-296; doi:10.3390/cancers6010240
Published: 27 January 2014
Abstract: Since its original identification as a leukocyte gelatinase/type V collagenase and tumour type IV collagenase, gelatinase B/matrix metalloproteinase (MMP)-9 is now recognised as playing a central role in many aspects of tumour progression. In this review, we relate current concepts concerning the many ways in which gelatinase B/MMP-9 influences tumour biology. Following a brief outline of the gelatinase B/MMP-9 gene and protein, we analyse the role(s) of gelatinase B/MMP-9 in different phases of the tumorigenic process, and compare the importance of gelatinase B/MMP-9 source in the carcinogenic process. What becomes apparent is the importance of inflammatory cell-derived gelatinase B/MMP-9 in tumour promotion, early progression and triggering of the “angiogenic switch”, the integral relationship between inflammatory, stromal and tumour components with respect to gelatinase B/MMP-9 production and activation, and the fundamental role for gelatinase B/MMP-9 in the formation and maintenance of tumour stem cell and metastatic niches. It is also apparent that gelatinase B/MMP-9 plays important tumour suppressing functions, producing endogenous angiogenesis inhibitors, promoting inflammatory anti-tumour activity, and inducing apoptosis. The fundamental roles of gelatinase B/MMP-9 in cancer biology underpins the need for specific therapeutic inhibitors of gelatinase B/MMP-9 function, the use of which must take into account and substitute for tumour-suppressing gelatinase B/MMP-9 activity and also limit inhibition of physiological gelatinase B/MMP-9 function.
Since the original identification of galetinase B/matrix metalloproteinase (MMP)-9, as a human leukocyte gelatinase [1,2,3,4], its characterisation as a type V collagenase , the observation that malignant tumour cells express an identical enzyme that associates with metastatic behaviour and degrades type IV collagen under certain conditions [6,7,8,9,10] and its subsequent cloning from HT-1080 fibrosarcoma cells , research into the physiological and pathological functions of gelatinase B/MMP-9, in contrast to almost all other MMPs, has continued to increase at a steady rate [12,13]. Gelatinase B/MMP-9 involvement in malignant tumour progression has now moved on from original concepts of an almost exclusive role in matrix degradation, associated with tumour invasion, to include roles in almost all aspects of tumour biology, ranging from initiation and early progression, to angiogenesis, dissemination, invasion and motility, formation of the cancer stem cell niche, regulation of tumour immunological surveillance, metastatic site preparation and promotion of metastatic growth.
In the present article, following a briefly description of the human gelatinase B/MMP-9 gene, protein and mechanisms that regulate its expression, activation and activity, we review current concepts concerning gelatinase B/MMP-9 involvement in tumour progression, starting with the genetic damage that results in transformation and accompanies tumorigenicity, neoplastic expansion and the accumulation of mutations, increased survival, tumour-associated angiogenesis, adhesive interactions, matrix degradation and the loss of basement membrane, tumour cell invasion, motility, intravasation and extravasation, evasion of immunological surveillance, and regulation of the cancer stem cell and metastatic niches. We also review tumour-associated mechanisms that alter the equilibrium between gelatinase B/MMP-9 and its inhibitors and address novel ways to inhibit gelatinase B/MMP-9 involvement in tumour progression.
2. The Gelatinase B/MMP-9 Gene and mRNA
The human gelatinase B/MMP-9 gene localises to chromosome 20q11.2-q13.1, consists of 7,654 bases, starting from 44,637,547 bp from pter to 44,645,200 bp from pter, and is arranged into 13 exons . The 2.2 kb gelatinase B/MMP-9 promoter resembles that of MMP-1 and MMP-3 rather than the MMP-2 one, and contains a TATA motif at position -29, GC box at position -563, TGF-beta inhibitory element at position -474, AP-1 elements at positions -79 and -209, three Ets binding PEA3 sites between -599 and -531, an NF-κB element at positions -600 and -328, two AP-2 elements and a (CA)n segment . Gelatinase B/MMP-9 is transcribed as a single 2.4 kb mRNA species and alternative splice variants have not been reported [15,16]. The gelatinase B/MMP-9 3'-UTR contains functional bindings sites for miR-491-5p, miR-885-5p  and miR-211 .
Gelatinase B/MMP-9 SNPs
A single C > T nucleotide polymorphism at position −1562 within the gelatinase B/MMP-9 promoter, originally associated with coronary atherosclerosis , deregulates gelatinase B/MMP-9 expression and associates with gastric tumour progression , susceptibility to oral squamous cell carcinoma [21,22,23], nasopharyngeal carcinoma , squamous cell carcinoma of the lung  and oesophageal squamous cell carcinoma , and also associates with a higher risk of metastasis in the Asian, but not the European population . Polymorphisms in the length of (CA)n sequence within the gelatinase B/MMP-9 promoter have been reported, with lengths of (CA)21 and (CA)23 shown to increase gelatinase B/MMP-9 transcription [28,29,30]. This region is close to TRE, SP1 and NF-κB cis elements and may alter their function. The (CA)n element binds a specific DNA binding protein, dependent upon CA number . The gelatinase B/MMP-9 polymorphism Rs1056628CC, detected within the Chinese population, is characterised by a change in base 2182 from A to C within the 3'-UTR miR491-5p binding sequence and increases gelatinase B/MMP-9 expression, potentially through altered miR-491-5p binding . Two gelatinase B/MMP-9 coding region single nucleotide polymorphisms rs2250889 (P574R) and rs17576 (R279Q) have been associated with risk of lung cancer and lung cancer metastasis , and with reduced overall survival of patients with loco regionally advanced nasopharyngeal carcinoma, characterised by increased tissue gelatinase B/MMP-9 expression [33,34], lymph node metastasis in gastric cancer  and risk of gallbladder cancer  but these SNPs do not appear to associate with colon cancer susceptibility in a Chinese cohort study . In addition to these reports, gelatinase B/MMP-9 coding region SNPs Arg279Gln and Arg668Gly may represent potential predictors of survival in Chinese patients with non-small cell lung cancer .
3. The Gelatinase B/MMP-9 Protein
We direct the reader to the excellent and extensive reviews by Van den Steen and colleagues, and Vandooren and colleagues [12,13], concerning gelatinase B/MMP-9 biochemistry and molecular biology. Briefly, the gelatinase B/MMP-9 protein is a multi-domain metallo-enzyme, with a catalytic site composed of a metal binding domain separated from the active site by three fibronectin repeats that facilitate the degradation of large substrates such as elastin and denatured collagens. Within this region the amino acids Asp309, Asn319, Asp232, Tyr320 and Arg3076 are important for gelatin binding. The catalytic site is maintained inactive by an amino-terminal pro-peptide PRCGXPD, with the cysteine coordinated with the catalytic Zn2+. The COOH terminus of gelatinase B/MMP-9 contains a hemopexin domain that regulates substrate binding, interacts with inhibitors and facilitates cell surface binding. A central O-glycosylated domain provides molecular flexibility, regulates gelatinase B/MMP-9 substrate specificity, gelatinase B/MMP-9-dependent invasion, interaction with TIMP and cell surface localisation. This domain facilitates the movement of gelatinase B/MMP-9 along macromolecular substrates and unwinds collagen initially cleaved by other enzymes, permitting gelatinase B/MMP-9-mediated degradation [12,13].
3.1. Gelatinase B/MMP-9 Catalytic Site
Within the gelatinase B/MMP-9 catalytic domain the amino acid Glu402 and Zn2+ ion are essential for function, amino acids Leu397 and Ala406 are important for general catalytic activity, Asp410 enhances type V collagenolytic activity, Pro415 enhances gelatinolytic activity  and Gly substitution of Glu415 renders gelatinase B/MMP-9 collagenolytic . The propeptide domain contains a “cysteine switch” sequence that binds to the catalytic Zn2+ ion, inhibiting catalytic activity. Gelatinase B/MMP-9 activation is achieved by proteolytic removal of this sequence by enzymes that include: trypsin, cathepsin G, kallikrien, elastase, chymase, neutrophil elastase and the MMPs-1, -2, -3, -7, -10, -13 and -26 . Debate exists, however, as to whether plasmin can directly activate gelatinase B/MMP-9 [12,41]. Indirect plasmin-mediated gelatinase B/MMP-9 activation is achieved via MMP-1, MMP-3 and MMP-7 . In addition to proteolytic gelatinase B/MMP-9 activation, agents that modify the interaction between the pro-peptide cysteine and the catalytic site Zn2+ ion, such as ionic detergents, organo-mercurials, oxidising agents, S-nitrosylation and S-glutothiolation can also activate gelatinase B/MMP-9 [12,42,43,44]. The gelatinase B/MMP-9 catalytic domain contains six disulphide bonds that are necessary for intracellular trafficking and gelatinase B/MMP-9 secretion . The gelatinase B/MMP-9 catalytic site also contains cryptic plasmin degradation sites that are exposed by divalent cation chelators and by the bisphosphonate alendronate (Fosamax) and upon degradation irreversibly inhibit gelatinase B/MMP-9 catalytic activity .
3.2. Gelatinase B/MMP-9 Hemopexin Domain
The gelatinase B/MMP-9 hemopexin domain exhibits a relatively unique covalent structure in which Cys516 and Cys704 form a disulphide bridge, which is involved in domain function but is not required for gelatinase B/MMP-9 secretion [45,46]. This domain facilitates interactions with substrates, gelatinase B/MMP-9 oligomerisation, binds the carboxyl terminal of TIMP-1, binds cell surface proteins such Ku70/80 and LRP, and upon binding appropriate substances, such as heme, also mediates autocatalytic gelatinase B/MMP-9 activation . Divergent disulphide bridging between the 17-cysteine residues within gelatinase B/MMP-9 regulates structure and function. Disulphide bridging within fibronectin repeats are essential for gelatinase B/MMP-9 secretion. Hemopexin domain function depends upon disulphide bridging and disulphide bridging between the O-glycosylation or hemopexin domains facilitates gelatinase B/MMP-9 dimerization or oligomerisation, promoting CD44 binding, which results in activation of the EGF receptor and subsequent ERK/1/2 mediated cancer cell migration [46,48]. Gelatinase B/MMP-9 hemopexin domain hetero-dimerization with proteins such as TIMP-1 and NGAL protects gelatinase B/MMP-9 against proteolytic degradation.
3.3. Gelatinase B/MMP-9 O-Glycosylation Domain
The O-glycosylated domain of gelatinase B/MMP-9, also known as the type V collagen-like domain, represents a 64 amino acid linker containing 22 proline residues, six glycine residues and approximately 12–14 O-linked glycans . This domain is active in hemopexin domain orientation, which is important for molecular interactions with exogenous proteins, including gelatinase B/MMP-9 substrates . The removal of this domain reduces gelatinase B/MMP-9 specificity for macromolecular substrates, including gelatin .
3.4. Truncated Gelatinase B/MMP-9 Isoforms
Several truncated gelatinase B/MMP-9 isoforms have been described that include proteolytically active fragments derived from autocatalysis and exogenous proteolytic degradation. The 65 kDa gelatinase B/MMP-9 catalytically active fragment generated by MMP-3 is deleted of COOH terminal sequence and escapes TIMP-1 inhibition. KLK7 and meprin-α also remove this domain from gelatinase B/MMP-9 [50,51,52]. A novel 82 kDa inactive pro-gelatinase B/MMP-9 form has been described in human leukaemic cells, which also escapes TIMP inhibition [53,54] and a similar sized human pro-gelatinase B/MMP-9 isoform is generated by the action of plasmin .
4. Gelatinase B/MMP-9 Substrates
Gelatinase B/MMP-9 was originally characterised as a gelatinase/V collagenase [1,2,3,4,5], and was later attributed type IV collagenolytic activity [6,11]. Although there is controversy surrounding the susceptibility  or resistance [8,40,56] of triple helical domains of collagens to degradation by gelatinase B/MMP-9, the capacity of gelatinase B/MMP-9 to degrade native type IV collagen may be limited, therefore, to non-triple helical, less-disulphide cross-linked or pre-digested molecular forms of type IV collagen [8,57,58]. It remains debatable whether activated gelatinases alone degrade type IV collagen within the context of an insoluble basement membrane [8,57,58,59]. Gelatinase B/MMP-9 does, however, degrade basement membrane laminin, disrupting basement membrane structure, tissue architecture  and inducing apoptosis . In addition to its capacity to degrade extracellular matrix components, recent reports have characterized an ever-increasing array of substrates susceptible to degradation by gelatinase B/MMP-9, dramatically widening the potential physiological and pathological sphere of gelatinase B/MMP-9 influence. Gelatinase B/MMP-9 exhibits substrate specificity for cytokines, chemokines and growth factors within the extracellular compartment and may also degrade nuclear, mitochondrial and cytoplasmic substrates (Table 1). For a broad spectrum of gelatinase B/MMP-9 substrates, both old and new, we direct reader to the following articles [52,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118].
|Table 1. Update of Gelatinase B/MMP-9 substrates. Substrates (sub) and MMP-9 origins are provided: human (hu), mouse (mu), bovine (bo) and rabbit (ra).|
|ECM Substrates||Collagen type I||(bo/mu sub/hu MMP-9)|||
|Collagen type II||(hu sub/MMP-9)|||
|Collagen III||(bo sub/hu MMP-9)|||
|Collagen IV||(hu/mu sub/MMP-9)||[8,57,58,66,67,68,69,70]|
|Collagen V||(hu sub/MMP-9)||[4,8,68]|
|Collagen VI||(hu sub/MMP-9)|||
|Collagen α1 and α2 (VI)||(hu sub/MMP-9)|||
|Collagen α1 (XI)||(hu sub/MMP-9)|||
|Collagen α1 (XVIII)||(hu sub/MMP-9)||[70,72]|
|Procollgen lysine-2-oxygluterate-5 dioxygenase-1||(hu sub/MMP-9)|||
|Galectin 3||(hu sub/MMP-9)|||
|Laminin||(mu sub/hu MMP-9)||[60,62,68]|
|Tenascin C||(hu sub/MMP-9)||[70,74,75]|
|Tenascin X||(hu sub/MMP-9)|||
|Insulin growth factor binding protein 4||(hu sub/MMP-9)|||
|Cystatin C||(hu sub/MMP-9)|||
|Elastin||(Bo/mu sub/hu/mu MMP-9)||[76,77]|
|Entactin||(mu sub/hu MMP-9)|||
|Heparan sulphate||(hu sub/MMP-9)|||
|Cell surface substrates||ICAM-1||(hu sub/MMP-9)||[81,82]|
|Laminin receptor||(Xenopus sub/hu MMP-9)|||
|Kit ligand||(mu/hu sub/MMP-9)||[90,91]|
|β2 integrin subunit||(mu sub/MMP-9)|||
|Occludin tight junction protein||(bo sub/huMMP-9)|||
|Syndecan 1 and 4||(mu sub/MMP-9)||[96,97]|
|Serpin α-1 proteinase inhibitor||(mu sub/MMP-9)|||
|myelin basic protein||(hu sub/MMP-9)|||
|NG2 Proteoglycan||(hu sub/MMP-9)|||
|β-distroglycan||(mouse substrate/MMP-9 ?)|||
|Soluble beta amyloid protein||(hu sub/MMP-9)||[102,103]|
|Fibrilar beta amyloid protein||(mu sub/MMP-9 ?)|||
|ADAMTS-4 (aggrecanase-1)||(hu sub/MMP-9)|||
|Candidate cell surface substrates||Angiopoetin 1 receptor Tie2||(hu sub/MMP-9)|||
|Neuropilin 1||(hu sub/MMP-9)|||
|Integrin α3||(hu sub/MMP-9)|||
|Clatherin heavy chain CLH17||(hu sub/MMP-9)|||
|Saposin A||(hu sub/MMP-9)|||
|Semaphorin 7A||(hu sub/MMP-9)|||
|CC Chemokines||CCL7||(mu sub/MMP-9)|||
|CCL11 (Eotaxin)||(mu sub/MMP-9)|||
|CCL17 (TARC)||(mu sub/MMP-9)|||
|CXC Chemokines||CXCL1/NAP-3||(hu sub/MMP-9)|||
|CXCL9/ MIG||(hu sub/MMP-9)|||
|CXCL6/GCP-2||(hu/mu sub/hu MMP-9)|||
|Other Substrates||Leukaemia inhibitory factor (LIF)||(hu sub/MMP-9)|||
|Protease nexin-1||(hu sub/MMP-9)|||
|Granulins precursor acrogranin||(hu sub/MMP-9)|||
|uPA precursor||(hu sub/MMP-9)|||
|tPA precursor||(hu sub/MMP-9)|||
|C1r-A||(mu sub/hu MMP-9)|||
|Pyruvate kinase isoenzymes M1/M2||(ra sub/hu MMP-9)|||
|Collagenase 3 (MMP-13)||(hu sub/MMP-9)|||
|Dickkopf-3 tumour suppressor||(hu sub/MMP-9)|||
|DJ-1 oncogene||(hu sub/MMP-9)|||
|Follistain-like 3||(hu sub/MMP-9)|||
|Neuron specific enolase||(hu sub/MMP-9)|||
|Nieman-Pick C2||(hu sub/MMP-9)|||
|Ym 1||(mu sub/MMP-9)|||
|S100A8 proinflammatory protein||(mu sub/MMP-9)|||
|S100A9 proinflammatory protein||(mu sub/MMP-9)|||
|Mature NGF||(mu sub/MMP-9)|||
|KISS-1 metastasis suppressor||(hu sub/MMP-9)|||
|VEGF||(mu sub/MMP-9 not hu MMP-9)||[80,118]|
5. Gelatinase B/MMP-9 Transcription and Translation
The 2.2 kb human gelatinase B/MMP-9 promoter contains a TATA-like motif at position −29 but no CAAT-like motif. Relative to the transcriptional start site, functional transcription sites include: an SP1 binding GC box located at −563, a retinoblastoma binding element or GT box that also binds SP1 at position −54, and three additional GT boxes. In addition to a TGF-β1 inhibitory element at −474 bp and 4 potential AP-1 binding elements, the functional AP-1 site at position −79 is essential for basal and jun/Fos induced expression in HT-1080 and osteosarcoma cells , three functional PEA3/Ets binding sites localise between −599 and −531 are also involved in basal gelatinase B/MMP-9 transcription [119,120]. A functional NF-κB binding site is located at −600 and a second site at −328 bp , and potentially functional inhibitory AP-2-like binding sites immediately upstream of the GC-box that interferes with Sp-1 binding , an alternating microsatellite CA sequence in close proximity to the AP1 site at position −79  (Figure 1).
Synergism between transcriptional elements characterises basal-, cytokine- and phorbol ester-induced gelatinase B/MMP-9 transcription, with the AP-1 element at position −79 necessary, but not sufficient for transcription, cooperating with NF-κB (−600) and SP1 (−563) elements, respectively . The NF-κB element (−600) is required for gelatinase B/MMP-9 transcription induced during spontaneous epithelial to neuroblast transition and by all-trans-retinoic acid in human neuroblastoma cells [123,124], by TNF-α in HT-1080 fibrosarcoma cells and rabbit fibroblasts [119,125,126], IL1β , Bcl2 , HIV-1-Tat , KiSS1 , synergistic combinations of cytokines and growth factors [126,131] and thioredoxin , acting in concert with other elements including the AP-1 site at position −79. The Ets element at −541 acting together with the AP-1 element at position −533 regulates gelatinase B/MMP-9 transcription induced by c-Ha- Ras, EGF and fibroblast cell contact [12,120,133]. Both RBE (−54) and AP-1 (−79) elements regulate v-Src induced gelatinase B/MMP-9 transcription in fibrosarcoma cells, c-Ha-Ras induced gelatinase B/MMP-9 transcription in adenocarcinoma cells and c-Ha-ras/v-myc-induced gelatinase B/MMP-9 transcription in rat embryo cells . The RBE element (−54) also functions together with the NF-κB element (−600) in gelatinase B/MMP-9 transcription induced by spontaneous epithelial to neuroblast conversion exhibited by SK-N-SH neuroblastoma cells . In general, gelatinase B/MMP-9 transcription with few exceptions depends upon the concerted interaction between several transcriptional cis elements and cognate transcription factors, with particular important roles highlighted for AP1 (−79) and NF-κB (−600) elements, with NF-κB and SP1 transcription factors specific determinant for gelatinase B/MMP-9 expression. Recently, a functional binding site for the E2 protein expressed by human oncogenic papilloma virus 8 has been characterised at position −1100 of the human MMP-9 promoter and shown to promote MMP-9 transcription .
The gelatinase B/MMP-9 protein is constitutively expressed by only a limited number of cell types, such as keratinocytes, macrophages, polymorphonuclear leukocytes and some malignant tumour cell lines, including MDA-MB-231 breast cancer, HT-1080 fibrosarcoma and A2058 melanoma cell lines [12,15] and is readily induced in wide range of normal and tumour cell types by pro-inflammatory cytokines, activators of PKC and growth factors with gelatinase B/MMP-9 expression regulated through inhibitory STAT and SMAD pathways and stimulatory PKC, Ras/MAPK, TRAD/TRAF, MEK/JNK, ASK/MKK and IRAK/TRAF pathways [12,13,15].
6. Gelatinase B/MMP-9 Expression, Bioavailability, Activity and Endogenous Inhibitors
Gelatinase B/MMP-9 expression is up-regulated in vitro by pro-inflammatory cytokines and PKC activators in human melanoma, neuroblastoma, teratocarcinoma, lung cancer and fibrosarcoma cells [15,16] and in rabbit fibroblasts , by chemokines in prostate cancer cells  and by growth factors, such as TGFβ in human breast cancer cells , EGF in human prostate , squamous cell carcinoma  and renal carcinoma cells , HGF in colon , renal , hepatocellular carcinoma , mesothelioma , lung cancer  and pancreatic tumour cells , by FGF in rabbit fibroblasts , human osteosarcoma cells , human bladder cancer cells  and human breast cancer cells [155,156], by neuropeptides in prostate cancer cell lines  and by haemoglobin in malignant melanoma and bladder cancer cells . Gelatinase B/MMP-9 is also induced in neuroblastoma cells in association with spontaneous epithelial to neuroblast phenotype conversion and following treatment with all-trans-retinoic acid [123,124] and released from IL-8 stimulated neutrophils .
Gelatinase B/MMP-9 enzymatic activity is inhibited by the universal systemic protease inhibitor α2-macrogloblin , members of the tissue inhibitors of metalloproteinases (TIMPs) family [161,162] and is also antagonized by its own isolated hemopexin domain [41,163]. TIMPs 1–4 are 20–30 kDa glycoprotein MMP inhibitors that depend upon disulphide bridges between 6 cysteine pairs for their inhibitory activity [161,162,164]. TIMP-1 exhibits a unique binding interaction with gelatinase B/MMP-9 and, with the exception of human neutrophils, exhibits a high level of coordinated expression with TIMP-1, is frequently secreted as a TIMP-1/gelatinase B/MMP-9 complex and binds gelatinase B/MMP-9 with high affinity, in contrast to TIMP-2 and TIMP-3 [12,15,41,123,157,162]. The interaction between pro-form gelatinase B/MMP-9 and TIMP-1 involves the C-terminal domains of both proteins and in this form TIMP-1 is available to inhibit other MMPs. Upon gelatinase B/MMP-9 activation, TIMP-1 inhibits gelatinase B/MMP-9 catalytic activity through N-terminal interaction with the gelatinase B/MMP-9 catalytic site, with inhibition facilitated by the gelatinase B/MMP-9 C-terminus, since it does not readily occur in gelatinase B/MMP-9 C-terminus deletion mutants. In contrast to TIMP-1, TIMP-2 inhibition of gelatinase B/MMP-9 depends upon the N-terminal domain, but does not involve C-terminal interaction and is less effective that TIMP-1. TIMP-3 is a matrix-associated inhibitor that interacts with and inhibits gelatinase B/MMP-9 to a lesser extent than either TIMP-1 or TIMP-2 [161,162].
The bioavailability of gelatinase B/MMP-9 is regulated by forming complexes with low-density lipoprotein receptor-related proteins (LRP)-1 and LRP2 via functional endocytosis, promoting intracellular gelatinase B/MMP-9 uptake and leupeptin-sensitive degradation [49,165]. Autocatalytic gelatinase B/MMP-9 degradation is prevented when monomeric gelatinase B/MMP-9 is complexed with Neutrophil gelatinase-associated lipocalin (NGAL) in an interaction that does not result in gelatinase B/MMP-9 inhibition, effectively prolonging enzymatic activity [166,167].
The Gelatinase B/MMP-9/TIMP-1 Protease-Antiprotease Equilibrium
Mechanisms that alter the equilibrium between gelatinase B/MMP-9 and its TIMP-1 inhibitor in favour of protease activity, facilitate gelatinase B/MMP-9 involvement in tumour pathology, and include differential expression, evasion from TIMP inhibition, and TIMP-1 inactivation.
Gelatinase B/MMP-9 and TIMP-1 are frequently co-ordinately expressed in a large number of cell types and secreted as a pro-gelatinase B/MMP-9/TIMP-1 complex [12,15]. The tumor environment is however complex, and composed of tumor, stromal and inflammatory elements that also contribute to the modulation of this important equilibrium. Tumor infiltrating neutrophils release gelatinase B/MMP-9 in TIMP-free form, facilitating tumor-associated differential gelatinase B/MMP-9 and TIMP-1 expression [168,169] Furthermore, the differential up-regulation of gelatinase B/MMP-9 but not TIMP-1 expression has been reported in human ovarian cancer , skin cancer , squamous cell carcinoma of the hypopharynx  and colon and rectal tumours in vivo , and has also been demonstrated in malignant melanomas induced in metallothionin/RET transgenic mice . In vitro, differential up-regulation of gelatinase B/MMP-9 but not TIMP-1 expression characterises PC-3 prostate tumor cell/stromal cell co-cultures and endothelial cells co-cultured with fibroblasts [175,176], cervical carcinoma cells in response to CD40L activation , human head and neck squamous carcinoma cells in response to c-erbB ligands , spontaneous epithelial to neuroblast transformation of human neuroblastoma cells , retinoic acid treatment of differentiation resistant human neuroblastoma cells , peroxiredoxin expression in metastatic human MDA-MB-231 breast cancer cells , thioredoxin expression in human MDA-MB-231 breast cancer cells  and bFGF treatment of human retinoblastoma cells .
Differential gelatinase B/MMP-9 and TIMP-1 regulation may also involve promoter SNPs and/or 3’-UTR micro RNA binding sites. Indeed, gelatinase B/MMP-9 SNPs that augment gelatinase B/MMP-9 expression have been associated with increased risk of different forms of cancer (See Section Gelatinase B/MMP-9 SNPs on page 241), as have altered levels of miRs that bind miR binding sites within the 3'-UTR region of gelatinase B/MMP-9. The miRs -211, 491-5p and 885-5p target and inhibit gelatinase B/MMP-9 expression and are down regulated in human glioblastoma multiforme, in association with increased gelatinase B/MMP-9 expression [17,18], and miR-19a has been reported to regulate gelatinase B/MMP-9 expression in colon cancer cells . Furthermore, a recent report has shown that miR-17 targets the TIMP-1 protein-coding region and its inhibition enhances TIMP-1 expression and decreases gelatinase B/MMP-9 activity . It is likely, therefore, that altered patterns of miR expression may also facilitate the differential expression of gelatinase B/MMP-9 and TIMP-1 in malignant tumours.
Extracellular activation of the thioredoxin redox system, up-regulated in malignant tumours, has been shown to inhibit TIMP but not MMP activity in vitro and in models of human neuroblastoma and UV irradiated dermal fibroblasts [164,183]. Furthermore, the myeloperoxidase/H202/hypochlorous acid (HOCl) system of inflammation induces the oxidative inactivation of TIMPs, whilst promoting the activation of MMPs, at concentrations found during inflammation [184,185], providing mechanisms through which the gelatinase B/MMP-9/TIMP equilibrium within tumours can be altered in favour of proteolytic activity even under conditions of high level TIMP expression . TIMP MMP-inhibitory activity, furthermore, can be destroyed by neutrophil elastase, trypsin and α-chymotrypsin, all of which activate gelatinase B/MMP-9 [12,187,188], providing an additional mechanism for irreversible TIMP inhibition combined with gelatinase B/MMP-9 activation within inflammatory tumour environments and also environments such as the pancreas, in which trypsin and trypsin-like enzymes are expressed . Finally, truncated gelatinase B/MMP-9 isoforms generated by enzymatic digestion or present on the cell surface of human leukemic cells have been shown to escape TIMP inhibition (see Section 3.4).
7. Gelatinase B/MMP-9, Tumour Initiation/Promotion and Genetic Instability
Potential pro-oncogenic roles for gelatinase B/MMP-9 have been reported, implicating gelatinase B/MMP-9 in neoplastic transformation, tumour initiation/promotion and genetic instability (Figure 2). Gelatinase B/MMP-9 localises to the nucleus, despite lack of classical nuclear localisation signal [190,191] and nuclear gelatinase activity associates with increased levels of DNA fragmentation [192,193,194]. Indeed, nuclear gelatinase degrades the nuclear matrix protein poly-ADP-ribose-polymerase (PARP), hindering DNA repair [193,195]. Furthermore, gelatinase B/MMP-9 binds the DNA damage heterodimer Ku70/80, providing a potential mechanism for its nuclear translocation . Nuclear gelatinase B/MMP-9 has been reported in human gliomas, astrocytomas and neuroblastomas [197,198].
Gelatinase B/MMP-9 has been reported to protect colorectal cancer cells against microsatellite instability, with reduced gelatinase B/MMP-9 activity associated with increased microsatellite instability. This has been attributed to inhibitory mutations within the promoter of the gelatinase B/MMP-9 activator MMP-3 and is associated with better prognosis [199,200,201]. Microsatellite instability, furthermore, down-regulates gelatinase B/MMP-9 expression by introducing polymorphisms that reduce the number of (CA)n repeats within gelatinase B/MMP-9 regulatory domain to below 22 .
A role for inflammatory neutrophil-derived gelatinase B/MMP-9 in intestinal adenoma initiation has been described in heterozygous APC (APC-min) knockout mice, with a 40% reduction in adenoma formation observed upon gelatinase B/MMP-9 knockout . Increased gelatinase B/MMP-9 activity provided by inflammatory neutrophils, furthermore, augments neutrophil recruitment via gelatinase B/MMP-9-mediated degradation and super-activation of IL-8 , augmenting neutrophil-mediated genetic instability [106,203]. Gelatinase B/MMP-9 also induces Rac1b alternative splice variant expression, which promotes chromosomal instability by increased reactive oxygen species levels and activating Snail-mediated transcription, resulting in increased oxidative DNA damage [204,205].
Gelatinase B/MMP-9 has also been reported to promote liver tumour initiation by the proteolytic release and activation of matrix-associated TGFβ and VEGF , and in human mammary epithelial cells induces cell surface expression of the HER2/Neu oncoprotein, inhibiting apoptosis and shifting normal mammary cells towards a transformed phenotype, in the presence of oestrogen .
In contrast, gelatinase B/MMP-9 optimises non-homologous end joining (NHEJ) DNA repair in human glioma cells. Indeed, down-regulation of gelatinase B/MMP-9 expression, combined with either urokinase or cathepsin B, delays DNA repair by lowering KU70/80 recruitment to damaged DNA. This reduces NHEJ DNA repair function, increases the levels of DNA damage and promotes apoptosis .
8. Gelatinase B/MMP-9 and Tumour Initiating Cell Proliferation and Expansion
Clonal expansion of transformed cells is also an essential step in tumour progression and is facilitated by inflammation and involves a change in equilibrium between proliferation, apoptosis and angiogenesis [209,210].
In the heterozygous APC knockout mouse model (APC-min), neutrophil-derived gelatinase B/MMP-9 stimulates adenoma initiating cell proliferation, promoting adenoma expansion, and implicating gelatinase B/MMP-9 in the expansion of tumour cell populations that lack full APC function. It is likely that this involves gelatinase B/MMP-9-mediated release and activation of non-matrix cytokines, such as TNFα and IL-1β and matrix-associated growth factors, such as VEGF, TGFβ and FGFs and/or the degradation of growth inhibitors [211,212,213,214]. Indeed, gelatinase B/MMP-9 degrades IGF-BPs augmenting the circulating levels of IGF, promoting astrocytoma growth , and increasing circulating VEGF and EGF levels , which also promote adenoma cell proliferation in APC-min mice. Furthermore, transcriptional silencing of gelatinase B/MMP-9 inhibits human glioma cells proliferation  and Wnt signalling induced by hypoxia stimulating gelatinase B/MMP-9 expression and promotes neural stem cell proliferation , suggesting that a hypoxia/Wnt/gelatinase B/MMP-9 axis may also promote proliferation of the cancer stem/progenitor cell component of neural-related tumours.
9. Gelatinase B/MMP-9, Stem Cells and the Cancer Stem Cell Niche
The stem cell niche is a unique, specialised location responsible for maintaining stem cells. Stem cells within the niche are anchored by intracellular and cell matrix adhesive interactions, which regulate stem cell numbers, stem cell self-renewal and potentially asymmetrical stem cell division. Normal stem cells and cancer stem cells exhibit similar behaviour [218,219]. Cancer stem cell niches have been identified in tumours and implicated in tumour heterogeneity, metastatic progression and therapeutic resistance, and are regulated by conditions within the tumour and promoted by tumour associated stress such as hypoxia [220,221]. Gelatinase B/MMP-9 has been implicated in regulating stem cell niche behaviour and within the bone marrow, degrading extracellular matrices within the stem cell niche, resulting in the activation and mobilisation of haemopoetic stem cells. This is facilitated by the conversion of stem cell factor from its membrane bound to free form, promoting c-Kit receptor-mediated stem cell proliferation . Gelatinase B/MMP-9 also releases circulating endothelial precursor stem cells from the bone marrow, contributing to angiogenesis . Interaction between stroma-derived factor (SDF)-1 and the chemokine receptor CXCR4 is essential for stem/progenitor cell function  and induces gelatinase B/MMP-9 expression. A similar interaction induces gelatinase B/MMP-9 expression in cancer cells, promoting dissemination and metastasis to bone [222,223,224]. Wnt signalling induces gelatinase B/MMP-9 expression and maintains stem cell niche integrity [225,226]. Wnt signalling is up regulated in cancer, and also stimulates cancer stem cell proliferation, resistance to apoptosis, tumour invasion and metastasis [227,228,229]. Furthermore, Wnt-induced gelatinase B/MMP-9 expression has been implicated in embryonic neural stem cells proliferation in conditions of hypoxia , a similar mechanism may, therefore, regulate cancer stem cells proliferation within neural tumours .
10. Gelatinase B/MMP-9 and Epithelial to Mesenchymal Transition (EMT)
Epithelial to mesenchymal transition (EMT) represents the conversion of polarized immotile epithelial cells into motile mesenchymal progenitor cells. This mechanism is important in development (type 1), normal wound healing or pathological fibrosis (type 2) and in the metastatic transformation of cancer cells (type 3) . Type 3 EMT is fundamental for tumour progression to metastasis, and is either re-activated in de-differentiated epithelial cancer cells or activated in epithelial cancer stem cells, inducing a more motile and invasive phenotype . It may also be transient, with metastatic cells reverting back to an epithelial phenotype at destination.
Gelatinase B/MMP-9 is an important EMT-related gene, and is not only a consequence but also a cause of EMT (Figure 3). Gelatinase B/MMP-9 cooperates with Snail transcription factor to induce EMT in epidermoid carcinoma cells , is involved in medulloblastoma cell EMT , is induced by Twist transcription factor an essential inducer of EMT [233,234,235] and by krupple like factor (KLF)-8, a critical component of FAK-regulated breast cancer EMT, which induces gelatinase B/MMP-9 expression in human breast cancer cells, promoting migration, invasion, angiogenesis and metastasis [234,235,236]. EMT in gastric cancer involves a Shh/PI3K/Akt/gelatinase B/MMP-9 pathway, which promotes metastatic dissemination to lymph nodes . In human neuroblastoma cells, spontaneous EMT-like phenotypic conversion from a less invasive epithelial to more invasive neuroblast phenotype, associates with the induction of gelatinase B/MMP-9 expression and increased gelatinase B/MMP-9-mediated invasion .
11. Gelatinase B/MMP-9 and Cancer-Related Inflammation
Inflammation is now considered to be a hallmark of tumour progression, and regulates tumour-associated angiogenesis, tumour cell proliferation, invasion and metastasis [209,210]. Gelatinase B/MMP-9 is considered to be a tuner and amplifier of inflammatory and immune functions [106,238] and is up regulated by pro-inflammatory cytokines such as TNFα, IL-1β, IL-6 and TGFβ in a wide variety of human tumour cells, stromal and endothelial cells [12,13,15]. Gelatinase B/MMP-9 activates pro-inflammatory cytokines TNFα and IL-1β, increases the activity of chemokines CXCL1, CXCL4, CXCL7 and CXCL8, releases TGFβ from matrix stores, is released by activated neutrophils in TIMP-1-free form and acts as a nanomolar effector of tumour associated inflammation [12,13]. Neutrophil-derived gelatinase B/MMP-9 also interacts with neutrophil NGAL, which prevent autolytic gelatinase B/MMP-9 processing but does not impair gelatinase B/MMP-9 activity, promoting tumour progression [130,161]. CXCL8 interaction with the chemokine receptor CXCR2 induces gelatinase B/MMP-9 release from neutrophils , and activation of the chemokine receptor CXCR4 up-regulates gelatinase B/MMP-9 expression in prostate tumour cells, promoting invasion and metastasis . Furthermore, myeloperoxidase/H2O2/HOCl system activation in neutrophils activates gelatinase B/MMP-9 and inhibits TIMP activity [184,185]. Gelatinase B/MMP-9, therefore, exhibits an integral relationship with tumour-associated inflammation. Indeed, the inhibition of gelatinase B/MMP-9 expression by inhibitors of pro-inflammatory cyclooxygenase-2 reduces tumour cell proliferation, invasion and metastasis [241,242]. In addition to its relationship with neutrophils, gelatinase B/MMP-9 also promotes macrophage and tumour cell invasion by cleaving the TGF-β-induced protein βig-h3, releasing it from the extracellular matrix, whereas non-degraded βig-h3 inhibits cell migration by promoting cell-cell contact and cell-extracellular matrix interactions .
In contrast to its tumour-promoting effects, high-level gelatinase B/MMP-9 expression has also been reported to promote tumour regression in a breast cancer model, augmenting neutrophil infiltration and promoting tumour-associated macrophage anti-tumour activity .
12. Gelatinase B/MMP-9 and Angiogenesis
The formation of new blood vessels is a highly orchestrated process that depends upon mitogenic and non-mitogenic angiogenic factors and involves matrix remodelling, cell migration, and regulated adhesive interactions between vascular cells and with the matrix. Tumour neovascularisation is fundamental for primary tumour expansion, metastatic progression and metastatic growth, and occurs via processes including sprouting angiogenesis, vasculogenesis, co-option inter-susception and/or vascular mimicry. Unlike normal vessels, blood vessels within tumours are abnormal, immature and inflammatory in nature .
Gelatinase B/MMP-9 is a critical pro-angiogenic molecule  and triggers the “angiogenic switch” in the quiescent vasculature [247,248] (Figure 4). Both host inflammatory and vascular gelatinase B/MMP-9 has been shown to be crucial for the development of the tumour angiogenic vasculature in models of pancreatic, ovarian and skin cancer [170,211,249]. Neutrophil gelatinase B/MMP-9 regulates pericyte proliferation, apoptosis and recruitment during angiogenesis  and mobilises the recruitment of bone marrow-derived angiogenic precursors to the tumour stroma enhancing the tumour angiogenic and vasculargenic process [90,250,251,252]. Gelatinase B/MMP-9 also triggers “the angiogenic switch” by mobilising and activating angiogenic mitogens from matrix stores at the onset of tumour-associated angiogenesis [169,211,251,253]. This process is facilitated by the release of TIMP-1-free gelatinase B/MMP-9 from neutrophils, which acts as an exceptionally potent nanomolar angiogenic factor, releasing both FGF and VEGF from matrices [169,254].
The gelatinase B/MMP-9/VEGF axis not only supports angiogenesis but also promotes hyperactive haematopoiesis, [255,256], which also promotes tumour progression by expanding myeloid-derived suppressors that suppress T-lymphocyte proliferation and activation, promoting tumour evasion of immune surveillance [257,258,259]. Mouse gelatinase B/MMP-9 has been shown to cleave VEGF to a truncated VEGF121 form that promotes irregular neovascularisation by altering interactions with heparan sulphate and other matrix components . This, however, does not appear to extend to human gelatinase B/MMP-9 .
In addition to promoting pericyte recruitment, gelatinase B/MMP-9 also promotes the recruitment of pro-angiogenic monocytes and CD34+ endothelial cell progenitors, which express VE-cadherin and VEGFR2, to tumours, markedly influencing angiogenesis [252,260,261,262,263] and induces the release of circulating endothelial precursor stem cells from the bone marrow by degrading c-kit ligand, contributing to both angiogenesis and vasculogenesis . In human neuroblastoma, gelatinase B/MMP-9 recruits bone marrow-derived leukocytes and support cells to tumour vessels, regulating vessel maturation  and the VEGF/gelatinase B/MMP-9 axis has been implicated in the robust angiogenic response associated with TrkAIII oncogene promotion of neuroblastoma tumorigenicity . In gelatinase B/MMP-9 knockout mice, impaired vascularisation associates with reduced pericyte-recruitment  and vascular pericytes have been shown to express gelatinase B/MMP-9 in human breast tumours . In general, knockout technology has implicated MMP9 in skeletal growth plate vascularisation  and in bone marrow derived CD11b+ myelomonocytic cell-mediated vasculogenesis in irradiated tumour tissues, with the absence of gelatinase B/MMP-9 associated with small tumours containing mature vessels . Gelatinase B/MMP-9 has also been implicated in capillary branching during ischemia-induced revascularisation .
Although, bone marrow-cell derived gelatinase B/MMP-9 appears to be sufficient for tumour vasculogenesis, it is not essential and can be substituted by gelatinase B/MMP-9 from either stromal, smooth muscle or tumour cell components. Indeed, fibroblast gelatinase B/MMP-9 enhances endothelial cell survival and function , gelatinase B/MMP-9 from circulating macrophages promotes angiogenesis in a model of pancreatic cancer  and increased tumour cell gelatinase B/MMP-9 promotes angiogenesis in a model of neuroblastoma .
Tumour-associated hypoxia is a major stimulus for angiogenesis and hypoxia exhibits an overall tendency to increase vascular gelatinase B/MMP-9 expression [273,274]. Neovascularization induced by hypoxia involves Nox2-derived ROS-mediated gelatinase B/MMP-9 activation  and under conditions of hypoxia gelatinase B/MMP-9 modulates endothelial cell behaviour, promoting human microvascular endothelial cell invasive and angiogenic capacity . Inflammatory cytokines TNFα, IL-17 and IL-18 promote gelatinase B/MMP-9 regulated migration of pericyte and vascular smooth muscle cell migration during angiogenesis [277,278,279,280] and gelatinase B/MMP-9 knockout impairs both pericyte and vascular smooth muscle cell migration, decreasing intimal vascular hyperplasia [281,282]. Furthermore, in addition to mobilising bone marrow CD34+ stem cells, gelatinase B/MMP-9 also promotes endothelial cell progenitor proliferation [262,263], degrades basement membrane type IV collagen, exposing cryptic αVβ3 integrin binding sites that promote angiogenesis  and releases VEGF from matrices in angiogenic islets, promoting angiogenesis [211,251].
In contrast to autocrine angiogenesis stimulating effects of gelatinase B/MMP-9 , gelatinase B/MMP-9 also exhibits capacity to negatively regulate angiogenesis by producing endogenous anti-angiogenic factors such as endostatin, tumstatin and angiostatin [72,112,284,285]. Endostatin, formed by gelatinase B/MMP-9 digestion of the type XVIII collagen α1 chain , blocks VEGFR2 and α5β1-mediated angiogenesis, inhibits gelatinase B/MMP-9 activity [286,287,288,289] and reduces metastasis in patients with high-grade transitional cell carcinoma of the bladder . Tumstatin, formed by gelatinase B/MMP-9 digestion of the collagen IV α3 chain, inhibits endothelial cells proliferation and promotes αVβ3-mediated endothelial cell apoptosis [235,239]. Angiostatin, formed by gelatinase B/MMP-9 digestion of plasminogen and plasmin [112,113], acts as a competitive inhibitor of tissue-type plasminogen activator and single chain urokinase-mediated plasminogen activation, inhibits plasmin-mediated laminin degradation, impairs plasminogen association with the tumour cell surface, and inhibits plasmin-dependent tumour invasion and angiogenesis [113,285]. The gelatinase B/MMP-9 hemopexin domain, which can be generated by plasmin-mediated degradation of cryptic sites within the gelatinase B/MMP-9 catalytic domain, also inhibits gelatinase B/MMP-9 activity and angiogenesis [41,163,291].
Other interactions involving gelatinase B/MMP-9 that regulate angiogenesis include: thrombospondin-1 induction of gelatinase B/MMP-9 expression but inhibition of gelatinase B/MMP-9 activation , and gelatinase B/MMP-9 interaction with syndecan-1, which promotes syndecan-1 shedding and enhances medulloblastoma cells tube forming capacity. This involves an gelatinase B/MMP-9/syndecan-1/miR-494 regulatory loop, involved in regulating irradiation-induced angiogenesis, in which syndecan and gelatinase B/MMP-9 activity negatively feedback to regulate miR494 expression, which promotes angiogenesis . Interaction between angiogenic endothelial cells and prostate cancer cells has also been reported to activate an IL-6/androgen receptor/TGFβ/gelatinase B/MMP-9 signal pathway that augments prostate cancer invasion in association with angiogenesis .
Angiogenic factors stimulate and/or associate with gelatinase B/MMP-9 expression. Ang2 expression correlates with that of gelatinase B/MMP-9 . VEGF induces gelatinase B/MMP-9 expression in vascular cells and some malignant tumour cell types [296,297,298]. Hypoxia induces VEGF-A expression resulting in the recruitment of pro-angiogenic neutrophils that deliver the gelatinase B/MMP-9 and trigger the “angiogenic switch” . Angiogenic fibroblast growth factors induce gelatinase B/MMP-9 expression in tumour and stromal tissues [153,300,301], and agents that inhibit MMP9 expression and/or gelatinase B/MMP-9 activity, such as DMBT , propofol , secreted protein acidic and rich in cysteine (SPARC) , S100A4 , xylitol , wortmanin , BMP4 , and aloe emodin , down regulate angiogenesis in different models.
Vasculargenic mimicry by tumour cells has been equated to tumour-associated angiogenesis . Gelatinase B/MMP-9 has been also implicated in the vasculargenic mimicry exhibited by Adriamycin-resistant MCF-7 breast cancer cells, promoting tubular network formation through a VEGF receptors VEGFR-2 and VEGFR-3-mediated mechanism, implicating gelatinase B/MMP-9 in tumour-associated vascular mimicry .
Gelatinase B/MMP-9 and Lymphangiogenesis
Lymphagiogenesis is also an important component of tumour progression, with lymphatic vessels providing important routes for metastatic dissemination [311,312]. Although gelatinase B/MMP-9 is not required for normal skin lymphangiogenesis , tumour induced lymphangiogenesis has been reported to involve a sonic hedgehog/PI3K/Akt/gelatinase B/MMP-9 pathway, leading to lymph node metastases in gastric cancer . Furthermore, neutrophil-derived gelatinase B/MMP-9 has been implicated in inflammation-associated lymphangiogenesis, promoting VEGF-A bioavailability and bioactivity  and, together with VEGF-C, has been implicated in lymphangiogenesis and lymph node metastasis in breast cancer .
13. Gelatinase B/MMP-9 and Disruption of Tissue Architecture
The loss of tissue architecture is one of the earliest hallmarks of premalignant epithelial cancer and results in tumour proliferation, local invasion and angiogenesis . In malignant breast cancer, tumour cells loose their capacity to form ordered structures and proliferate as disorganised colonies . Raf/MEK/ERK-mediated induction of gelatinase B/MMP-9 expression results in the destruction of breast tissue architecture, during breast cancer initiation, by degrading basement membrane laminin and destroying basement membrane integrity. This results in de-regulated tissue polarity and the loss of growth control (Figure 4). Gelatinase B/MMP-9 inhibition halts this process by preserving basement membrane integrity, which in turn reverses phenotype, arrests growth and re-establishes a differentiated acinar polarity .
14. Gelatinase B/MMP-9 Induction of Intracellular Signalling
Gelatinase B/MMP-9 interacts with the cellular surface through either Ku70/80 , CD44 [48,318] or via integrins . Gelatinase B/MMP-9 interacts with αL, β5, α4 and β1 subunits through its catalytic site and interacts with CD44, α4, β5 and β1 subunits through the hemopexin domain [319,320]. These interactions stimulate migration, promote survival, increase both proteolytic and non-proteolytic invasion [318,320,321,322] and promote angiogenesis . Signalling events in these interactions include, JNK involvement in gelatinase B/MMP-9-mediated dendritic cell migration, which is blocked by the JNK inhibitor SP600125 , and MAPK and IP3K involvement in gelatinase B/MMP-9-induced endothelial cell migration, which is blocked by the MAPK inhibitor PD98059 and by the IP3K inhibitor LY294002. Apoptosis in medulloblastoma, associated with loss of gelatinase B/MMP-9 expression, involves β1 integrin, ERK signalling and NF-κB activation [324,325]. Gelatinase B/MMP-9 interaction with α4β1 and CD44 induces survival signalling in CLL cells, activating lyn kinase, phosphorylating STAT and up-regulating Mcl-1 expression . Interaction between gelatinase B/MMP-9 and CD44 results in EGF receptor activation and signalling through ERK, Akt and FAK, which promotes tumour cell invasion and migration , with FAK coordinating adhesion, polarisation, migration, invasion, survival and death .
15. Gelatinase B/MMP-9, Tumour Cell Invasion and Motility
Within the tumour context, gelatinase B/MMP-9 was originally identified as a novel type IV collagenolytic protease secreted by metastatic Ras transformed fibroblasts and implicated in basement membrane disruption required for tumour invasion and metastasis [6,7]. Although it remains debatable as to whether gelatinase B/MMP-9 alone can effectively degrade type IV collagen within the context of an insoluble basement membrane matrix, gelatinase B/MMP-9 promotes invasion by disrupting basement membrane structure by degrading basement membrane laminin and type IV collagen, in concert with other enzyme systems [8,57,59,60]. Interaction between tumour cells and stroma at the invasive edge regulates gelatinase B/MMP-9 expression, which combined with gelatinase B/MMP-9 released by tumour-associated neutrophils and macrophages, increases invasiveness [175,328,329,330] (Figure 5).
Tumor cell invasion is, however, a complex process that depends upon alterations in protein expression, interaction between tumour, inflammatory and stromal cells, altered intercellular and extracellular adhesive interactions, and changes in the tumour microenvironment. It is regulated by pro-inflammatory cytokines, chemokines, growth factors, matrix components, integrin and non-integrin receptors, proteases and inhibitors, and depends upon the cellular motile response. Cellular motility is achieved by different mechanisms and can reversibly switch between mesenchymal and amoeboid migration, which promote invasion as either single cells or collective chains, sheets, columns, tubes or clusters .
Protease involvement in migration and invasion is relatively restricted to mesenchymal motility, whereas amoeboid motility does not require proteolytic activity but involves a high level of cellular deformability, low affinity substrate binding and cycles of morphological contraction and expansion [331,332]. Mesenchymal migration, on the other hand, requires high affinity binding to integrin and non-integrin receptors. During mesenchymal migration, integrin or non-integrin receptors concentrate to membrane lamellipodia, filopodia, pseudopodia and invadopodia, promoting adapter protein-mediated intracellular interaction with the actin cytoskeleton. This results in the formation of focal contacts and adhesions with extracellular matrix components, the maturation of which activates intracellular focal adhesion kinases (FAKs) that form transient signalling complexes with Src kinases, promoting movement by inducing the turnover of focal contact providing the propulsive force for movement by continually modifying of cell-matrix interactions. These events depend upon proteolytic activity and involve the fibronectin integrin receptors α5β1 or αVβ6, the laminin integrin receptors α6β1 or α6β4, the fibronectin/vitronectin integrin receptor αVβ3 and the fibrillar collagen receptor α2β1 .
Gelatinase B/MMP-9 regulates mesenchymal migration, co-localises with integrins at lamellipodia on migrating cells  and co-operates with αVβ3 integrin to increase breast cancer cell migration and metastatic capacity . FAK-Src signalling through JNK transcriptionally upregulates gelatinase B/MMP-9 expression, promoting gelatinase B/MMP-9-mediated invasion [335,336,337], and αVβ6 or α5β1 interaction with fibronectin also increases gelatinase B/MMP-9 expression, and gelatinase B/MMP-9-mediated migration and invasion of squamous cell carcinoma and melanoma cells [338,339,340]. Fibronectin also induces gelatinase B/MMP-9 expression in ovarian cancer cells through FAK and ras activation  and laminin has been shown to up-regulate gelatinase B/MMP-9 expression in macrophages and in A2058 melanoma cells but not in other malignant tumour cells [341,342]. Gelatinase B/MMP-9 promotes chain migration of neural crest cells  and collective migration of epithelial cancer cells, in association with EMT .
Gelatinase B/MMP-9 also interacts with the non-integrin receptor CD44, concentrating gelatinase B/MMP-9 to cell extensions, which control the turnover of adhesive interactions and extracellular matrix degradation required for motility, in a coordinated process that also involves ezrin, actin and Krp1 . Gelatinase B/MMP-9 interaction with CD44 also promotes breast cancer cell migration and invasion in association with EGFR activation . An N-cadherin/FGFR/gelatinase B/MMP-9 axis has been implicated in breast cancer cell invasion and metastasis, bypassing E-cadherin invasion and metastasis suppressing signals . Gelatinase B/MMP-9 degradation of protease nexin-1 has also been implicated in a novel pathway through which gelatinase B/MMP-9 regulates tumour cell invasion, impairing the capacity of nexin to bind and down-regulate the activity of uPA .
In contrast to these reports, gelatinase B/MMP-9 has also been shown to degrade the β4 component of α6β4 integrin, de-regulating sheet migration of epithelial cells . Furthermore, gelatinase B/MMP-9 interaction with α4β1 integrin and CD44 on the surface of chronic leukemic cells has been shown to inhibit migration in response to chemotactic gradients . Tumour cells, furthermore, can undergo mesenchymal to amoeboid transition (MAT). Gelatinase B/MMP-9 is not required for amoeboid movement through 3D interstitial matrices  and MAT has been shown to increase metastatic capacity in association with reduced gelatinase B/MMP-9 expression .
Gelatinase B/MMP-9 and Primary Tumour Cell Escape
In order to escape the constraints of the primary tumour, tumor cells invade, move and alter their adhesive interactions. Chemotactic motile responses may direct tumour cells to lymphatic or blood vessels and tumour interaction, with tumour associated macrophages facilitating directional movement within tumours . HGF activation of tumour cell c-met induces gelatinase B/MMP-9 expression, increasing tumor cell motility and scattering .
16. Gelatinase B/MMP-9 and Immunological Surveillance
The capacity to evade elimination by immunological/inflammatory mechanisms is an essential feature of tumour progression to metastasis. Gelatinase B/MMP-9 is an important regulator of both innate and tumour immune responses . This is illustrated in gelatinase B/MMP-9 knockout mice, which do not resolve contact hypersensitivity reactions, implicating gelatinase B/MMP-9 in the down regulation of the immune response , suggesting an analogous role for gelatinase B/MMP-9 in cancer. In support of this, gelatinase B/MMP-9 expression associates with that of anti-pathogen immune-response-related genes in late stage compared to early stage lung tumours, although it remains to be determined whether any of these represent novel gelatinase B/MMP-9 substrates . Gelatinase B/MMP-9 degrades ICAM-1, down-regulating leukocyte homing  and promotes evasion of the immune system by chronic myeloid leukemia cells by solubilizing cell membrane ICAM-1 . Gelatinase B/MMP-9 degrades the IL-2 receptor α, repressing activation and proliferation of tumour infiltrating T-lymphocytes in cervical cancer [85,86]. Gelatinase B/MMP-9 degrades Surfactant protein D (SP-D), an important component of innate immune defence, leading to loss of innate immune function, limiting SP-D involvement in tumour immunology and renders oncology patients more susceptible to infection . Gelatinase B/MMP-9 digests C1q complement component at a site required for interaction with the C1qR02 receptor, repressing C1q/C1qR02 involvement in tumour immunology  and may also degrade complement component C1r . C5a induces the expression of the gelatinase B/MMP-9 stimulator IL-1β in monocytes [15,354] and the complement membrane attack complex induces gelatinase B/MMP-9 expression in cells protected against MAC-mediated lysis by CD59 , suggesting that activation of the complement system may promote tumour-associated gelatinase B/MMP-9 expression. Gelatinase B/MMP-9 also degrades the β2 subunit of macrophage CD18 integrin receptor, important for macrophage recruitment .
A role for gelatinase B/MMP-9 has also been reported in the development of tumour tolerance. This has been attributed to gelatinase B/MMP-9 induction of tolerogenic dendritic cells (tDC), through the release and activation of TGFβ, which increases the number of regulatory T (Treg) lymphocytes that promote tumour tolerance by suppressing CD8+ cytotoxic T cells [356,357,358]. In support of this, inhibition of gelatinase B/MMP-9 expression blocks tDC development and increases tDC and Treg numbers in cancer tissues [356,358,359,360,361]. Furthermore, the VEGF/gelatinase B/MMP-9 axis promotes hyperactive haematopoiesis, expanding myeloid-derived suppressors of T-lymphocyte proliferation and activation, which results in the repression tumour immune surveillance, which promotes tumour progression [255,256,257,258,259].
17. Gelatinase B/MMP-9 Haematogenous and Lymphatic Metastatic Dispersal
Tumour cell intravasation represents an important mechanism for haematogenous metastatic dissemination. The breaching of the vascular wall is considered to represent a rate limiting step for intravasation and consequently for haematogenous metastasis .
Gelatinase B/MMP-9 has been implicated in intravasation and subsequent metastasis formation  (Figure 6), with a particular role for inflammatory neutrophil-derived gelatinase B/MMP-9 highlighted in the promotion of haematogenous tumour cell dispersion of HT1080 fibrosarcoma and PC3 prostate carcinoma cells in xenograft models . Neutrophil-derived gelatinase B/MMP-9 involvement in tumour-associated intravasation requires neutrophil attraction to the activated endothelial cell surface, neutrophil activation and release of TIMP-1-free gelatinase B/MMP-9. Activation of TIMP-1 free gelatinase B/MMP-9 releases angiogenic factors stored within the extracellular matrix, which promote endothelial sprouting and new vessel formation, and gelatinase B/MMP-9-assisted tumour cell intravasation and dissemination . In support of this, gelatinase B/MMP-9 expression correlates with the intravasation and metastatic dissemination of HT-1080 fibrosarcoma cells, which is inhibited by the gelatinase B/MMP-9 inhibitor marimistat . Furthermore, keratinocyte growth factor induces gelatinase B/MMP-9 expression and venous invasion by pancreatic cancer cells .
Gelatinase B/MMP-9 has also been implicated in lymphatic dissemination of colon cancer to lymph nodes. This mechanism involves gelatinase B/MMP-9 and the chemokine receptor CCR7. C-C chemokine interaction with CCR7 promotes gelatinase B/MMP-9 expression and lymphatic dissemination of colon cancer, whereas CCR7 knockdown reduces gelatinase B/MMP-9 expression lymphatic dissemination and lymph node metastases, implicating the CCR7/gelatinase B/MMP-9 axis in lymphatic metastatic dissemination of colon cancer . In gastric cancer, lymphatic dissemination and lymph-node metastasis associate with increased expression of both Twist and gelatinase B/MMP-9 .
18. Gelatinase B/MMP-9 and Extravasation
After tumour cells that arrest in the microvasculature of distant organs they either extravasate or grow within vessels [366,367], adding to the debate as to whether extravasation is indeed a critical step in the metastatic process [368,369]. Due to the positive contribution made by inflammatory cells to the metastatic process, inflammatory cell-derived gelatinase B/MMP-9 may promote extravasation, as may tumour cell derived gelatinase B/MMP-9. Alternatively, endothelial cell clusters within metastatic sites may be primed to produce gelatinase B/MMP-9 by circulating VEGF through VEGF receptors , which may facilitate tumour cell extravasation across an already compromised vascular BM.
19. Gelatinase B/MMP-9 and the Metastatic Niche
Gelatinase B/MMP-9 appears to be one of the genes required for tumor metastasis [6,9,10,12,369]. Organ specific metastatic tropism characterises the metastatic process and is a complex process that involves interaction between infiltrating cancer cells and the local environment . Within the bone marrow, gelatinase B/MMP-9 regulates the recruitment and mobilization of hematopoietic stem and progenitor cells from the quiescent bone marrow niche to the proliferative niche, suggesting that gelatinase B/MMP-9 may play a similar role in cancer stem behaviour within the bone environment. In this process, gelatinase B/MMP-9 activated within the bone marrow, degrades anchorage proteins enabling haematopoietic stem cell (HSC) migration from the osteoblastic to the vascular niche, which promotes their proliferation . This involves gelatinase B/MMP-9 degradation of soluble kit-ligand mobilizing factor from its membrane-associated moiety and also degradation of osteopontin, which together induce stem cell cycling and reduces anchorage to the osteoblastic niche . Furthermore, osteoclasts activated within bone enhance gelatinase B/MMP-9 proteolytic activity, inducing further degradation of the endosteal-niche components osteopontin and membrane bound-stem cell factor . Since cancer stem and normal stem cells share molecular machinery and cancer stem cells hijack physiological stem cell trafficking mechanisms , gelatinase B/MMP-9 is likely to play a similar role in stimulating the proliferation cancer stem cells that locate to the bone metastatic niche.
Within non-bone metastatic niches, increased circulating levels of gelatinase B/MMP-9 have been shown to enhance the frequency of colon cancer metastasis to lung in a mouse model. This also associates with reduced size of metastases resulting from reduced tumour vascularisation associated with increased circulating angiostatin levels . Furthermore, distant primary tumours have been shown to induce gelatinase B/MMP-9 in pre-metastatic lung endothelial cell clusters via VEGF receptor-1 signalling, pre-conditioning lungs to metastatic growth, indicating that distant tumours can aggressively determine specific metastatic sites by activating endothelial cells at secondary sites [296,373], in a process involving gelatinase B/MMP-9 expressed by endothelial cells and tumor-associated macrophages that fertilizes the soil necessary for metastatic growth . Many metastatic tumours also release membrane vesicles that gain access to the circulation. Micro-vesicles shed by renal cancer stem cells contain pro-angiogenic factors, including gelatinase B/MMP-9, and promote the formation of a pre-metastatic niche, which is associated with unfavourable outcome . Circulating hematopoietic CD45 and Col1a positive fibrocytes have also been shown to predispose the lung to B16/F10 metastases by recruiting Ly-6C (+) monocytes, in a chemokine and gelatinase B/MMP-9-dependent manner . Furthermore, stromal derived factor (SDF)-1 interaction with the chemokine receptor CXCR4, which is essential for normal stem/progenitor cell function, promotes carcinogenesis, metastasis  and trans-endothelial migration of cancer cells by stimulating gelatinase B/MMP-9 secretion, disrupting basement membrane and inducing vascular permeability, promoting tumour cell extravasation. This mechanism promotes cancer stem cell homing to specific metastatic niches and in particular to the bone metastatic niche [222,378].
20. Gelatinase B/MMP-9, Apoptosis, Survival and the Mitochondria
Gelatinase B/MMP-9 regulates cellular survival and apoptosis [195,379]. Pro apoptotic effects have been described for gelatinase B/MMP-9 in the presence of proneurotrophins , in cerebellar neurons and retinal ganglion apoptosis [381,382], in hypertrophic growth plate chondrocytes  and in HL60 pro-myelocytic leukaemia cells . Pro-survival effects of gelatinase B/MMP-9 have also been described during angiogenesis, through the release and activation of mitogens from matrix stores . Gelatinase B/MMP-9 localises to mitochondria via Hsp70/Hsp60, and can disrupt mitochondrial structure, function and induce mitochondrial mtDNA damage, leading to diabetic retinal capillary cell apoptosis and gelatinase B/MMP-9 inhibition protects mitochondria from ultra-structural, functional and DNA damage [384,385,386], suggesting that gelatinase B/MMP-9 inhibitors may protect against mitochondrial apoptosis. Within the extracellular environment, gelatinase B/MMP-9 promotes neuronal apoptosis by degrading basement membrane laminin . In contrast, siRNA down regulation of gelatinase B/MMP-9 expression induces apoptosis in human glioblastoma cells in association with Fas death receptor-mediated caspase 3 and caspase 8 cleavage, implicating gelatinase B/MMP-9 in protecting glioblastoma cells against Fas ligand-mediated apoptosis . Methylation of the miR-211 gene up-regulates gelatinase B/MMP-9 expression in glioblastoma stem cells and increases their resistance to radiotherapy and chemotherapy-induced death . The activation of α4β1 and CD44 bound gelatinase B/MMP-9 induces lyn/STAT/MCL-1 signalling and apoptosis in chronic lymphocytic leukemia cells, that depends upon gelatinase B/MMP-9 hemopexin and O-glycosylation domains [318,322] and in human medulloblastoma cells inhibition of gelatinase B/MMP-9 expression promotes apoptosis through β1 integrin and ERK activation . In human mammary epithelial cells gelatinase B/MMP-9 expression reduces apoptosis by up regulating cell surface Her2/Neu expression .
21. Lessons from Gelatinase B/MMP-9 Knockout and Transgenics
Gelatinase B/MMP-9 knockout reduces intestinal adenoma formation and progression within the context of the APC-min mouse model, and has identified an important role for gelatinase B/MMP-9 released by inflammatory neutrophils in the formation, proliferation and progression of intestinal adenomas in cells, exhibiting compromised APC oncosoppressor function . In contrast, gelatinase B/MMP-9 elimination in Myc/BclXl and RIP1-Tag2 models of pancreatic neuroendocrine carcinogenesis impairs tumour angiogenesis but promotes tumor invasion in association with a shift in inflammatory cell content to cathepsin expressing CD11b/Gr1 positive cells at the invasive front. Plasticity in tumour inflammatory infiltrates, therefore, can alter tumour-associated protease expression to compensate for gelatinase B/MMP-9 loss, helping to explain the MMP inhibitor-induced tumour progression described in human late stage tumor clinical trials . Tumours, unable to grow in gelatinase B/MMP-9 knockout mice, grow readily following auto-transplantiation of normal mouse bone marrow by a mechanism independent of endothelial cell progenitors but involving CD11b positive myelomonocytic cells. In this model gelatinase B/MMP-9 is required for tumor-associated vasculogenesis . Human pancreatic cancer cell growth, impaired in gelatinase B/MMP-9 knockout mice, is promoted by gelatinase B/MMP-9 produced by parabiosed normal stromal cells, implicating stromal gelatinase B/MMP-9 in tumour progression . Gelatinase B/MMP-9 knockout mice also exhibit substantial inhibition of spontaneous metastasis due to impaired triggering of the “angiogenic switch” , and in experimental metastasis models, lung metastasis formation by both melanoma and lung carcinoma cells is reduced [390,391]. The inhibition of skin and ovarian cancer metastasis formation in gelatinase B/MMP-9 knockout mice can be reversed by transplantation of normal bone marrow cells, implicating inflammatory cell gelatinase B/MMP-9 in the metastatic process and adding to the role of gelatinase B/MMP-9 in primary tumour initiation, promotion and expansion [170,390].
In contrast to these reports, transgenic α1 integrin mice exhibit increased gelatinase B/MMP-9 expression and produce high level of circulating angiostatin, which reduces primary and metastatic growth of orthotopic cancers, in association with reduced angiogenesis. This identifies an anti-angiogenic, tumour suppressing function for gelatinase B/MMP-9 [392,393,394].
In mice transgenic for the gelatinase B/MMP-9 inhibitor TIMP-1, paradoxical effects have been described, with high circulating TIMP-1 inhibiting DMBA-induced mammary tumour growth, blocking tumorigenesis at an early stage . In contrast, high circulating TIMP-1 promotes subcutaneous B16 melanoma growth in association with increased angiogenesis, whilst suppressing metastatic lung colonisation . High circulating TIMP-1 levels, furthermore, strongly promote liver fibrosis , implicating gelatinase B/MMP-9 in normal liver physiology, adding to its physiological roles in the nervous system, inflammation and immunology [12,13,398].
22. Gelatinase B/MMP-9 Inhibitors and Future Directions
More than 50 broad-spectrum MMP inhibitors have been subjected to clinical trials. However, despite impressive results in non-randomized clinical trials, phase II and III clinical trials in patients with a range of different cancers have not been positive, due to a combination of factors that include a lack of understanding of the complexities of MMP involvement in tumour pathogenesis and progression, the lack of inhibitor specificity, drug intolerance and problems with drug dosage [399,400,401]. This was somewhat expected considering reports that several MMPs, including gelatinase B/MMP-9, display anti-tumor activity [72,112,113,284,285,402,403], different MMPs may be involved in different stages of tumour progression and the most potent endogenous gelatinase B/MMP-9 inhibitor, TIMP-1 may promote scattered micro-metastases in the liver . Therefore, the detailed characterisation of exact roles played by the different MMPs within tumour pathogenesis and progression is required, as is the development of highly specific MMP inhibitors.
The impressive quantity of data concerning gelatinase B/MMP-9 involvement in the different phases of tumor progression, reviewed in this article, highlights particularly important roles for inflammatory leukocyte-derived gelatinase B/MMP-9 in tumour initiation and early progression and a more complex involvement of gelatinase B/MMP-9 from inflammatory, stromal and tumour sources in the continued progression of tumours to metastasis. Furthermore, reports also suggest that under certain conditions gelatinase B/MMP-9 may also protect against tumour progression by promoting the formation of systemic inhibitors of angiogenesis, may promote apoptosis and also facilitate anti-tumor inflammatory and immunological reactions (see Section 11 and Section 16). Furthermore, it is also evident that under conditions of MMP inhibition malignant tumour cells compensate by undergoing mesenchymal to amoeboid transition, facilitating protease-independent progression .
Current gelatinase B/MMP-9 inhibitors can be divided into those that inhibit gelatinase B/MMP-9 expression or catalytic activity. NSAIDs and HMG-CoA reductase inhibitors inhibit gelatinase B/MMP-9 transcription . Gelatinase B/MMP-9 inhibitory siRNA inhibits gelatinase B/MMP-9 expression and tumorigenicity in a model of medulloblastoma  and miR-491-5p, miR-885-5p and miR-211 inhibit gelatinase B/MMP-9 expression and involvement in models of human glioblastoma [17,18]. Gelatinase B/MMP-9 activity can be blocked by the broad range MMP inhibitors d-penicillamine, hydroxamates, bisphosphonates and tetracyclins, . An active site-specific gelatinase B/MMP-9 inhibitory antibody REGA-3G12 has been reported , and bisphosphonates inhibit both gelatinase B/MMP-9 expression and activity [41,255]. Zoledronic acid has been shown to inhibit macrophage gelatinase B/MMP-9 and reduces angiogenesis in a model of papillomavirus-induced cervical cancer . Alendronate inhibits gelatinase B/MMP-9 activity and promotes plasmin-mediated destruction of the gelatinase B/MMP-9 catalytic domain, promoting irreversible gelatinase B/MMP-9 inhibition and producing inhibitory gelatinase B/MMP-9 hemopexin fragments, suggesting a novel rational for Alendronate use in pathology dependent upon gelatinase B/MMP-9 activity and plasminogen activation .
However, with the exception of REGA-3G12, there are few specific inhibitors of gelatinase B/MMP-9 catalytic activity, attesting to the close similarity exhibited by MMP catalytic sites. A HFDDDE motif of the gelatinase B/MMP-9 catalytic domain interferes with pro-gelatinase B/MMP-9 binding of β2 integrin, inhibits OCI-AML3 leukemia cells transmigration across a human endothelial cell layers and inhibits gelatinase B/MMP-9-mediated extracellular matrix degradation, suggesting potential use in therapeutic reduction of acute myeloid leukemia cells extra medullary infiltration . The peptides CTTHWGFTLC and GRENYHGCTTHWGHTLC also inhibit gelatinase B/MMP-9 catalytic activity but not gelatinase B/MMP-9 activation and inhibit primary HSC-3 tongue carcinoma growth but not tumor spread in a mouse model .
Recent approaches have also focussed on molecules that interfere with gelatinase B/MMP-9 activity mediated by the hemopexin and/or O glycosylation domains. Recombinant or isolated gelatinase B/MMP-9 hemopexin domain inhibits gelatinase B/MMP-9 activity [41,163], hampers colorectal cancer cell adhesion and migration , inhibits gelatinase B/MMP-9-induced functions in chronic lymphocytic Leukemia B cells , and inhibits angiogenesis in glioblastoma xenografts . A peptide mimic of integrin beta chain that binds the gelatinase B/MMP-9 hemopexin domain inhibits gelatinase B/MMP-9 binding to αVβ5 integrin, prevents progelatinase B/MMP-9 activation, inhibits HT-1080 fibrosarcoma cell invasion in vitro and HSC-3 tongue carcinoma xenograft growth in vivo but does not inhibit gelatinase B/MMP-9 activity . Peptide mimics of the first and fourth blades of the gelatinase B/MMP-9 hemopexin domain block gelatinase B/MMP-9 dimerization and inhibit HT-1080 and MDA-MB-435 tumour cell motility . The compound N-[4-(difluoromethoxy) phenyl]-2-[(4-oxo-6-propyl-1H-pyrimidin-2-yl) sulfanyl]-acetamide also binds to the gelatinase B/MMP-9 hemopexin domain, inhibits gelatinase B/MMP-9 homo-dimerization, blocks gelatinase B/MMP-9 mediated migration and reduces xenograft tumorigenicity and metastasis of MDA-MB-435 human breast cancer cells . Deletion of the O-glycosylation domain inhibits macromolecular substrate specificity of gelatinase B/MMP-9 , suggesting that inhibitors of O-glycosylation domain function may also be effective inhibitors of gelatinase B/MMP-9 function. Therefore, molecules that interact, interfere or compete with these two domains hold some promise in the development of specific therapeutic inhibitors of gelatinase B/MMP-9 activity and function. When considering the potential therapeutic use of specific gelatinase B/MMP-9 inhibitors, however, potential anti-tumor activity of gelatinase B/MMP-9 (i.e., production of anti-angiogenic molecules) must be taken into account and attempts made also to limit inhibitor interference with physiological gelatinase B/MMP-9 functions.
There is no doubt that gelatinase B/MMP-9 plays a fundamental role in tumour biology, ranging from initiation/promotion to angiogenesis, dissemination, immunological surveillance and metastatic growth. Gelatinase B/MMP-9, however, also exhibits anti-tumor activity and plays important physiological functions. It is therefore essential that specific inhibitors of gelatinase B/MMP-9 proteolytic and non-proteolytic functions are developed in order to determine the potential therapeutic efficacy of inhibiting gelatinase B/MMP-9 function in cancer therapy. The difficulty will be to inhibit the tumour promoting functions of gelatinase B/MMP-9, whilst substituting for anti-tumor gelatinase B/MMP-9 effects and minimising the inhibition of physiological gelatinase B/MMP-9 function.
This work was supported by grants from AIRC, Italian Ministry of University Research and the Maugeri Foundation.
Conflicts of Interest
The authors declare no conflicts of interest.
- Sopata, I.; Dancewicz, A.M. Presence of a gelatin-specific proteinase and its latent form in human leukocytes. Biochim. Biophys. Acta 1974, 370, 510–523. [Google Scholar] [CrossRef]
- Murphy, G.; Bretz, U.; Baggiolini, M.; Reynolds, J.J. The latent collagenase and gelatinase of human polymorphonuclear neutrophil leukocytes. Biochem. J. 1980, 192, 517–525. [Google Scholar]
- Dewald, B.; Bretz, U.; Baggiolini, M. Release of gelatinase from a novel secretory compartment of human neutrophils. J. Clin. Investig. 1982, 70, 518–525. [Google Scholar] [CrossRef]
- Hibbs, M.A.; Hasty, K.A.; Seyer, J.M.; Kang, A.H.; Mainardi, C.L. Biochemical characterisation of the secreted forms of human neutrophil gelatinase. J. Biol. Chem. 1985, 260, 2493–2500. [Google Scholar]
- Hibbs, M.A.; Hoidal, J.R.; Kang, A.H. Expression of a metalloproteinase that degrades native type V collagen and denatured collagens by cultured human alveolar macrophages. J. Clin. Investig. 1987, 80, 1644–1650. [Google Scholar] [CrossRef]
- Ballin, M.; Gomez, D.E.; Sinha, C.C.; Thorgeirsson, U.P. Ras oncogene mediated induction of a 92kDa metalloproteinase; strong correlation with the malignant phenotype. Biochem. Biophys. Res. Commun. 1988, 154, 832–838. [Google Scholar] [CrossRef]
- Ballin, M.; Mackay, A.R.; Hartzler, J.L.; Nason, A.; Pelina, M.D.; Thorgeirsson, U.P. Ras levels and metalloproteinase activity in normal versus neoplastic rat mammary tissues. Clin. Exp. Metastasis 1991, 9, 179–189. [Google Scholar] [CrossRef]
- Mackay, A.R.; Hartzler, J.L.; Pelina, M.D.; Thorgeirsson, U.P. Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen. J. Biol. Chem. 1990, 265, 21929–21934. [Google Scholar]
- Bernhardt, E.J.; Gruber, S.B.; Muschel, R.J. Direct evidence linking expression of matrix metalloproteinase 9 (92 kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA 1994, 91, 4293–4297. [Google Scholar] [CrossRef]
- Bernhardt, E.J.; Muschel, R.J.; Hughes, E.N. Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res. 1990, 50, 3872–3877. [Google Scholar]
- Wilhelm, S.M.; Collier, I.M.; Marmer, B.L.; Eisen, A.Z.; Grant, G.A.; Goldberg, G.I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase, which is identical to that secreted by normal human macrophages. J. Biol. Chem. 1989, 264, 17213–17221. [Google Scholar]
- Van den Steen, P.E.; Dubois, B.; Nelissen, I.; Rudd, P.M.; Dwek, R.A.; Opdenakker, G. Biochemistry and Molecular biology of gelatinase B or matrix metalloproteinase-9 (gelatinase B/MMP-9). Crit. Rev. Biochem. Mol. Biol. 2002, 37, 375–536. [Google Scholar] [CrossRef]
- Vandooren, J.; van den Steen, P.E.; Opdenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (gelatinase B/MMP-9): The next decade. Crit. Rev. Biochem. Mol. Biol. 2013, 48, 222–272. [Google Scholar] [CrossRef]
- Hutala, P.; Tuuttila, A.; Chow, L.T.; Lohi, J.; Keski, O.J.; Tryggvason, K. Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression of the 92- and 72- kilodalton enzyme genes in HT-180 cells. J. Biol. Chem. 1991, 266, 16485–16490. [Google Scholar]
- Mackay, A.R.; Ballin, M.; Pelina, M.D.; Farina, A.R.; Nason, A.M.; Hartzler, J.L.; Thorgeirsson, U.P. Effect of phorbol ester and cytokines on matrix metalloproteinase expression and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 1992, 12, 168–184. [Google Scholar]
- Masure, S.; Billiau, A.; van Damme, J.; Opdenakker, G. Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate. Biochim. Biophys. Acta 1990, 1054, 317–325. [Google Scholar] [CrossRef]
- Yan, W.; Zhang, W.; Sun, L.; Liu, L.; You, G.; Wang, Y.; Kang, C.; You, Y.; Jiang, T. Identification of gelatinase B/MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res. 2011, 1411, 108–115. [Google Scholar]
- Asuthkar, S.; Velpula, K.K.; Chetty, C.; Gorantla, B.; Rao, J.S. Epigenetic regulation of miRNA-211 by gelatinase B/MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget 2012, 3, 1439–1454. [Google Scholar]
- Zhang, B.; Ye, S.; Herrmann, S.M.; Eriksson, P.; de Maat, M.; Evans, A.; Arveiler, D.; Luc, G.; Cambien, F.; Hamsten, A.; et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99, 1788–1794. [Google Scholar] [CrossRef]
- Matsumura, S.; Oue, N.; Nakayama, H.; Kitadai, Y.; Yoshida, K.; Yamaguchi, Y.; Imai, K.; Nakachi, K.; Matsusaki, K.; Chayama, K.; et al. A single nucleotide polymorphism in the gelatinase B/MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J. Cancer Res. Clin. Oncol. 2005, 131, 19–25. [Google Scholar] [CrossRef]
- Tu, H.F.; Wu, C.H.; Kao, S.Y.; Liu, C.J.; Liu, T.Y.; Liu, M.T. Functional -1562 C to T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male area users. J. Oral Pathol. Med. 2007, 36, 409–414. [Google Scholar] [CrossRef]
- Vairaktaris, E.; Vassiliou, S.; Nkenke, E.; Serefoglou, Z.; Derka, S.; Tsigris, C.; Vylliotis, A.; Yapijakis, C.; Neukam, F.W.; Patsouris, E. A metalloproteinase-9 polymorphism which affects expression is associated with increased risk of oral squamous cell carcinoma. Eur. J. Surg. Oncol. 2008, 34, 450–455. [Google Scholar] [CrossRef]
- Vairaktaris, E.; Serefoglou, Z.; Avgoustidis, D.; Yapijakis, C.; Critselis, E.; Vylliotis, A.; Spyridonidou, S.; Derka, S.; Vassiliou, S.; Nkenke, E.; et al. Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol. 2009, 45, 247–253. [Google Scholar] [CrossRef]
- Nasr, H.B.; Mestiri, S.; Chahed, K.; Bounaouina, N.; Gabbouj, S.; Jalbout, M.; Chouchane, L. Matrix metalloproteinase-1 (-16076) 1G/2G and -9 (-1562) C/T promoter polymorphisms: Susceptibility and prognostic implications in nasopharyngeal carcinomas. Clin. Chim. Acta 2007, 384, 57–63. [Google Scholar] [CrossRef]
- Rollin, J.; Regina, S.; Vourc’h, P.; Lochman, S.; Blechet, C.; Reverdiau, P.; Gruel, Y. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 2007, 56, 273–280. [Google Scholar] [CrossRef]
- Wu, J.; Zhang, L.; Luo, H.; Zhu, Z.; Zhang, C.; Hou, Y. Association of matrix metalloproteinase-9 gene polymorphisms with genetic susceptibility to oesophageal squamous cell carcinoma. DNA Cell. Biol. 2008, 27, 553–557. [Google Scholar] [CrossRef]
- Liu, D.; Guo, H.; Li, Y.; Xu, X.; Yang, K.; Bai, Y. Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: A meta-analysis. PLoS One 2012, 7, e31251. [Google Scholar]
- Shimajiri, S.; Arima, N.; Tanimoto, A.; Murata, Y.; Hamada, T.; Wang, K.Y.; Sasaguri, Y. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 1999, 455, 70–74. [Google Scholar]
- Maeda, S.; Haneda, M.; Guo, B.; Koya, D.; Hayashi, K.; Sugimoto, T.; Isshiki, K.; Yasuda, H.; Kashiwagi, A.; Kikkawa, R. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int. 2001, 60, 1428–1434. [Google Scholar] [CrossRef]
- Peters, D.G.; Kassam, A.; St. Jean, P.L.; Yonas, H.; Ferrell, R.E. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999, 30, 2612–2616. [Google Scholar] [CrossRef]
- Yuan, M.; Zhan, Q.; Duan, X.; Song, B.; Zeng, S.; Chen, X.; Yang, Q.; Xia, J. A functional polymorphism at miR-491–5p binding site in the 3'-UTR of gelatinase B/MMP-9 gene confers increased risk for atherosclerotic cerebral infarction in a Chinese population. Atherosclerosis 2013, 226, 447–452. [Google Scholar] [CrossRef]
- Hu, Z.; Huo, X.; Lu, D.; Qian, J.; Zhou, J.; Chen, Y.; Xu, L.; Ma, H.; Zhu, J.; Wei, Q.; et al. Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin. Cancer Res. 2005, 11, 5433–5439. [Google Scholar] [CrossRef]
- Liu, H.; Huang, P.Y.; Tang, L.Q.; Chen, Q.Y.; Zhang, H.; Zhang, L.; Guo, L.; Luo, D.H.; Mo, H.Y.; Xiang, Y.Q.; et al. Functional polymorphisms of matrix metalloproteinase-9 and survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with radiotherapy. Med. Oncol. 2013, 30, 685. [Google Scholar] [CrossRef]
- Liu, Z.; Li, L.; Yang, Z.; Luo, W.; Li, X.; Yang, H.; Yao, K.; Wu, B.; Feng, W. Increased expression of gelatinase B/MMP-9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 2010, 10, 270. [Google Scholar] [CrossRef]
- Tang, Y.; Zhu, J.; Chen, L.; Chen, L.; Zhang, S.; Lin, J. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer. Clin. Cancer Res. 2008, 14, 2870–2877. [Google Scholar] [CrossRef]
- Sharma, K.L.; Misra, S.; Kumar, A.; Mittal, B. Higher risk of matrix metalloproteinase (MMP-2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants in gallbladder cancer. Liver Int. 2012, 32, 1278–1286. [Google Scholar] [CrossRef]
- Yang, Z.H.; Li, S.N.; Liu, J.X.; Guo, Q.X.; Sun, X.W. MMP-9 polymorphisms are related to serum lipids levels but not associated with colorectal cancer susceptibility in Chinese population. Mol. Biol. Rep. 2012, 39, 9399–9404. [Google Scholar] [CrossRef]
- Jin, G.; Miao, R.; Hu, Z.; Xu, L.; Huang, X.; Chen, Y.; Tian, T.; Wei, Q.; Boffetta, P.; Shen, H. Putative functional polymorphisms of MMP-9 predict survival of NSCLC in a Chinese population. Int. J. Cancer 2009, 124, 2172–2178. [Google Scholar] [CrossRef]
- O’Farrell, T.J.; Pourmotabbed, T. Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes. Role of fibronectin-like domain and active site of gelatinase B. J. Biol. Chem. 2000, 275, 27964–27972. [Google Scholar]
- O’Farrell, T.J.; Guo, R.; Hasegawa, H.; Pourmotabbed, T. Matrix metalloproteinase-1 takes advantage of the induced fit mechanism to cleave the triple-helical type I collagen molecule. Biochemistry 2006, 45, 15411–15418. [Google Scholar] [CrossRef]
- Farina, A.R.; Cappabianca, L.; di Ianni, N.; Ruggeri, P.; Ragone, M.; Merolla, S.; Gulino, A.; Mackay, A.R. Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain. FEBS Lett. 2012, 586, 2366–2374. [Google Scholar] [CrossRef]
- Triebel, S.; Blaser, J.; Reinke, H.; Knauper, V.; Tschesche, H. Mercurial activation of human PMN leukocyte type IV procollagenase (gelatinase). FEBS Lett. 1992, 298, 280–284. [Google Scholar] [CrossRef]
- Okamoto, T.; Akaike, T.; Sawa, T.; Miyamoto, Y.; van del Vliet, A.; Maeda, H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutothiolation via disulphide S-oxide formation. J. Biol. Chem. 2001, 276, 29596–29602. [Google Scholar]
- Gu, Z.; Kaul, M.; Yan, B.; Kridel, S.J.; Cui, J.; Strongin, A.; Smith, J.W.; Liddington, R.C.; Lipton, S.A.S. nitrosylation of matrix metalloproteinases: Signalling pathway to neuronal cell death. Science 2002, 297, 1186–1190. [Google Scholar] [CrossRef]
- Kahn, M.M.G.; Simizu, S.; Suzuli, T.; Masuda, A.; Kawatani, M.; Muroi, M.; Dohmae, N.; Nad Osada, H. Protein disulphide isomerase-mediated disulphide binds regulate gelatinolytic activity and secretion of matrix metalloproteinase-9. Exp. Cell Res. 2012, 318, 904–911. [Google Scholar] [CrossRef]
- Dufour, A.; Sampson, N.S.; Li, J.; Kuscu, C.; Rizzo, R.C.; Deleon, J.L.; Zhi, J.; Jaber, N.; Liu, E.; Zucker, S.; et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011, 71, 4977–4988. [Google Scholar] [CrossRef]
- Geurts, N.; Martens, E.; van Aelst, I.; Proost, P.; Opdenakker, G.; van den Steen, P.E. Beta-haematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. Biochemistry 2008, 47, 2689–2699. [Google Scholar] [CrossRef]
- Dufour, A.; Zucker, S.; Sampson, N.S.; Kuscu, C.; Cao, J. Role of matrix metalloproteinase-9 dimers in cell migration: Design of inhibitory peptides. J. Biol. Chem. 2010, 285, 35944–35956. [Google Scholar] [CrossRef]
- Van den Steen, P.E.; van Aelst, I.; Hvidberg, V.; Piccard, H.; Fiten, P.; Jacobsen, C.; Moestrup, S.K.; Fry, S.; Royle, L.; Wormald, M.R.; et al. The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition of binding to cargo receptors. J. Biol. Chem. 2006, 281, 18626–18637. [Google Scholar] [CrossRef]
- Bellini, T.; Trentini, A.; Manfrinato, M.C.; Tamborino, C.; Volta, C.A.; di Foggia, V.; Fainardi, E.; Dallocchio, F.; Castellazzi, M. Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms. J. Biochem. 2012, 151, 493–499. [Google Scholar] [CrossRef]
- Geurts, N.; Becker-Pauly, C.; Martens, E.; Proost, P.; van den Steen, P.E.; Stoker, W.; Opdenakker, G. Meprins process matrix metalloproteinase-9 (gelatinase B/MMP-9)/gelatinase B and enhance the activation kinetics by MMP-3. FEBS Lett. 2012, 586, 4264–4269. [Google Scholar] [CrossRef]
- Ramani, V.C.; Kaushal, G.P.; Haun, R.S. Proteolytic activation of kallikrien-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal domains. Biochim. Biophys. Acta 2011, 1813, 1525–1531. [Google Scholar] [CrossRef]
- Reis, C.; Lottspeich, F.; Dittmann, K.H.; Petrides, P.E. HL60 leukemia cells produce an autocatalytically truncated form of matrix metalloproteinase-9 with impaired sensitivity to inhibition by tissue inhibitors of metalloproteinases. Leukemia 1996, 10, 1520–1526. [Google Scholar]
- Reis, C.; Pitsch, T.; Mentele, R.; Zahler, S.; Egea, V.; Nagase, H.; Jochum, M. Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells: (Auto-) catalytic activation and resistance to inhibition by TIMP-1. Biochem. J. 2007, 405, 547–558. [Google Scholar] [CrossRef]
- Bigg, H.F.; Rowan, A.D.; Barker, M.D.; Cawston, T.E. Activity of matrix metalloproteinase-9 against native collagen I and II. FEBS J. 2007, 274, 1246–1255. [Google Scholar] [CrossRef]
- Van den Steen, P.E.; Proost, P.; Brand, D.D.; Kang, A.H.; van Damme, J.; Opdenakker, G. Generation of glycosylated remnant epitopes from human type II collagen by gelatinase B. Biochemistry 2004, 43, 10809–10816. [Google Scholar] [CrossRef]
- Eble, J.A.; Ries, A.; Lichy, A.; Mann, K.; Stanton, H.; Gavrilovic, J.; Murphy, G.; Kuhn, K. The recognition sites of the integrins α1β1 and α2β1 within collagen IV are protected against gelatinase A attack in the native protein. J. Biol. Chem. 1996, 271, 30964–30970. [Google Scholar]
- Shoji, A.; Kabeya, M.; Sugawara, M. Real-time monitoring of matrix metalloproteinase-9 collagenolytic activity with a surface plasmon resonance biosensor. Anal. Biochem. 2011, 419, 53–60. [Google Scholar] [CrossRef]
- Mackay, A.R.; Corbitt, R.H.; Hartzler, J.L.; Thorgeirsson, U.P. Basement membrane type IV collagen degradation: Evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res. 1990, 50, 5997–6001. [Google Scholar]
- Beliveau, A.; Mott, J.D.; Lo, A.; Chen, E.I.; Koller, A.A.; Yaswen, P.; Muschler, J.; Bissel, M.J. Raf-induced MMP-9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vitro. Genes Dev. 2010, 24, 2800–2811. [Google Scholar] [CrossRef]
- Gu, Z.; Cui, J.; Brown, S.; Fridman, R.; Mobashery, S.; Strongin, A.Y.; Lipton, S.A. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 2005, 25, 6401–6408. [Google Scholar] [CrossRef]
- Xu, D.; Suenaga, N.; Edelman, J.; Fridman, R.; Muschel, R.; Kessler, B.M. Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol. Cell. Proteomics 2008, 7, 2215–2228. [Google Scholar] [CrossRef]
- Cauwe, B.; van den Steen, P.E.; Opdenakker, G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 2007, 42, 113–115. [Google Scholar] [CrossRef]
- Cauwe, B.; Opdenakker, G. Intracellular substrate cleavage: A novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 2010, 45, 351–423. [Google Scholar] [CrossRef]
- Prudova, A.; auf dem Keller, U.; Butler, G.S.; Overall, C.M. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol. Cell. Proteomics 2010, 9, 894–911. [Google Scholar] [CrossRef]
- Gioia, M.; Monaco, S.; van den Steen, P.E.; Sbardella, D.; Grasso, G.; Marini, S.; Overall, C.M.; Opdenakker, G.; Coletta, M. The collagen binding domain of gelatinase A modulates degradation of collagen IV by gelatinase B. J. Mol. Biol. 2009, 386, 419–434. [Google Scholar] [CrossRef]
- Murphy, G.; Reynolds, J.J.; Bretz, U.; Baggiolini, M. Partial purification of collagenase and gelatinase from human polymorphonuclear leucocytes. Analysis of their actions on soluble and insoluble collagens. Biochem. J. 1982, 203, 209–221. [Google Scholar]
- Morodomi, T.; Ogata, Y.; Sasaguri, Y.; Morimatsu, M.; Nagase, H. Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT-1080 fibrosarcoma cells. Biochem. J. 1992, 285, 603–611. [Google Scholar]
- Kridel, S.J.; Chen, E.; Kotra, L.P.; Howard, E.W.; Mobashery, S.; Smith, J.W. Substrate hydrolysis by matrix metalloproteinase-9. J. Biol. Chem. 2001, 276, 20572–20578. [Google Scholar]
- Stegemann, C.; Didangelos, A.; Ballarobre-Barriero, J.; Langley, S.R.; Mandal, K.; Jahangiri, M.; Mayr, M. Proteomic identification of matrix metalloproteinase substrates in the human vasculature. Circ. Cardiovasc. Genet. 2013, 6, 106–117. [Google Scholar] [CrossRef]
- O’Farrell, T.J.; Pourmattabbed, T. The fibronectin-like domain is required for the type V and XI collagenolytic activity of gelatinase B. Arch. Biochem. Biophys. 1998, 354, 24–30. [Google Scholar] [CrossRef]
- Ferreras, M.; Felbor, U.; Lenhard, T.; Olsen, B.R.; Delaissé, J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000, 486, 247–251. [Google Scholar] [CrossRef]
- Ochieng, J.; Fridman, R.; Nagia-Makker, P.; Kleiner, D.E.; Liotta, L.A.; Stetler-Stevenson, W.G.; Raz, A. Galectin-3 is a novel substrate for human matrix metalloproteinase-2 and 9. Biochemistry 1994, 33, 14109–14114. [Google Scholar] [CrossRef]
- Zampila, R.; Lopez, E.F.; Chiao, Y.A.; Dai, Q.; Escobar, G.P.; Hakala, K.; Weintraub, S.T.; Lindsey, M.L. Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventrical post-myocardial infaction. Proteomics 2010, 10, 2214–2223. [Google Scholar] [CrossRef]
- Siri, A.; Knauper, V.; Veirana, N.; Caocci, F.; Murphy, G.; Zardi, L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J. Biol. Chem. 1995, 270, 8650–8654. [Google Scholar]
- Katsuda, S.; Okada, Y.; Okada, Y.; Imai, K.; Nakanishi, I. Matrix metalloproteinase-9 (92-kd gelatinase/type IV collagenase equals gelatinase B) can degrade arterial elastin. Am. J. Pathol. 1994, 145, 1208–1218. [Google Scholar]
- Lau, A.C.; Duong, T.T.; Ito, S.; Yeung, R.S. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum. 2008, 58, 854–863. [Google Scholar] [CrossRef]
- Imai, K.; Shikata, H.; Okada, Y. Degradation of vitronectin by matrix metalloproteinases-1, -2, -3, -7 and 9. FEBS Lett. 1995, 369, 249–251. [Google Scholar] [CrossRef]
- Sires, U.I.; Griffin, G.L.; Broekelmann, T.J.; Mecham, R.P.; Murphy, G.; Chung, A.E.; Welgus, H.G.; Senior, R.M. Degradation of entactin by matrix metalloproteinases. J. Biol. Chem. 1993, 268, 2069–2074. [Google Scholar]
- Hawinkels, L.J.A.C.; Ziudwijk, K.; Verspaget, H.W.; de Jong-Muller, E.S.M.; van Duijin, W.; Ferreira, V.; Fontijn, R.D.; David, G.; Hommes, D.W.; Lamers, C.B.H.W.; et al. VEGF release by MMP-9 mediated heparin sulphate cleavage induces colorectal cancer angiogenesis. Eur. J. Cancer 2008, 44, 1904–1913. [Google Scholar] [CrossRef]
- Fiore, E.; Fusco, C.; Romero, P.; Stamenkovic, I. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002, 21, 5213–5223. [Google Scholar] [CrossRef]
- Sultan, S.; Gosling, M.; Nagase, H.; Powell, J.T. Shear stress-induced shedding of soluble intercellular adhesion molecule-1 from saphenous vein endothelium. FEBS Lett. 2004, 564, 161–165. [Google Scholar] [CrossRef]
- Andolfo, A.; English, W.R.; Resnati, M.; Murphy, G.; Blasi, F.; Sidenius, N. Metalloproteinase cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb. Haemost. 2002, 88, 298–306. [Google Scholar]
- Amano, T.; Kwak, O.; Fu, L.; Marshak, A.; Shi, Y.B. The matrix metalloproteinase stromelysin-3 cleaves laminin receptor at two distinct sites between the transmembrane domain and laminin binding sequence within the extracellular domain. Cell Res. 2005, 15, 150–159. [Google Scholar] [CrossRef]
- Sheu, B.C.; Hsu, S.M.; Ho, H.N.; Lien, H.C.; Huang, S.C.; Lin, R.H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001, 61, 237–242. [Google Scholar]
- De Paiva, C.S.; Yoon, K.-C.; Pangelinan, S.B.; Pham, S.; Puthenparambi, L.M.; Chuang, E.Y.; Farley, W.J.; Stern, M.E.; Li, D.-C.; Pflugfelder, S.C. Cleavage of functional IL-2 receptor alpha chain (CD25) from murine corneal and conjunctival epithelial by MMP-9. J. Inflamm. Lond. 2009, 6, 31. [Google Scholar] [CrossRef]
- Mohan, M.J.; Seaton, T.; Mitchell, J.; Howe, A.; Blackburn, K.; Burkhart, W.; Moyer, M.; Patel, I.; Waitt, G.M.; Becherer, J.D.; et al. The tumor necrosis factor-alpha converting enzyme (TACE): A unique metalloproteinase with highly defined substrate selectivity. Biochemistry 2002, 41, 9462–9469. [Google Scholar] [CrossRef]
- Ito, A.; Mukaiyama, A.; Itoh, Y.; Nagase, H.; Thogersen, I.B.; Enghild, J.J.; Sasaguri, Y.; Mori, Y. Degradation of interleukin 1 beta by matrix metalloproteinases. J. Biol. Chem. 1996, 271, 14657–1460. [Google Scholar]
- Schonbeck, U.; Mach, F.; Libby, P. Generation of biologically active IL-1 beta by matrix metalloproteinases: A novel caspase-1-independent pathway of IL-1 beta processing. J. Immunol. 1998, 161, 3340–3346. [Google Scholar]
- Heissig, B.; Hattori, K.; Dias, S.; Friedrich, M.; Ferris, B.; Hackett, N.R.; Crystal, R.G.; Besmer, P.; Lyden, D.; Moore, M.A.; et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediate release of kit-ligand. Cell 2002, 109, 625–637. [Google Scholar] [CrossRef]
- Hollenbeck, S.T.; Sakakibara, K.; Faries, P.L.; Workhu, B.; Liu, B.; Kent, K.C. Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. J. Surg. Res. 2004, 120, 288–294. [Google Scholar] [CrossRef]
- Vaisar, T.; Kassim, S.Y.; Gomez, I.G.; Green, P.S.; Hargarten, S.; Gough, P.J.; Parks, W.C.; Wilson, C.L.; Raines, E.W.; Heinecke, J.W. MMP-9 sheds the beta2 integrin subunit (CD18) from macrophages. Mol. Cell. Proteomics 2009, 8, 1044–1060. [Google Scholar] [CrossRef]
- Yu, Q.; Stamenkovic, I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD-44-mediated tumor invasion. Genes Dev. 1999, 13, 35–48. [Google Scholar] [CrossRef]
- Lue, H.-W.; Yang, X.; Wang, R.; Qian, W.; Xu, R.Z.H.; Lyles, R.; Osunkoya, A.O.; Zhou, B.P.; Vessella, R.L.; Zayzafoon, M.; et al. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated Erk signalling. PLoS One 2011, 6, e27720. [Google Scholar] [CrossRef]
- Giebel, J. S.; Menicucci, G.; McGuire, P. G.; Das, A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab. Invest. 2005, 85, 597–607. [Google Scholar] [CrossRef]
- Fitzgerald, M.L.; Wang, Z.; Park, P.W.; Murphy, G.; Bernfield, M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signalling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J. Cell. Biol. 2000, 148, 811–824. [Google Scholar] [CrossRef]
- Brule, S.; Charnaux, N.; Sutton, A.; Ledoux, D.; Chaigneau, T.; Saffar, L.; Gattegno, L. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 2006, 16, 488–501. [Google Scholar] [CrossRef]
- Liu, Z.; Zhou, X.; Shapiro, S.D.; Shipley, J.M.; Twining, S.S.; Diaz, L.A.; Senior, R.M.; Werb, Z. The serpin alpha-1 proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000, 102, 647–655. [Google Scholar] [CrossRef]
- Proost, P.; van Damme, J.; Opdenakker, G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 1993, 192, 1175–1181. [Google Scholar] [CrossRef]
- Larsen, P.H.; Wells, J.E.; Stallcup, W.B.; Opdenakker, G.; Young, V.W. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 2003, 23, 11127–11135. [Google Scholar]
- Agrawal, S.; Anderson, P.; Durbeej, M.; van Rooijen, N.; Ivars, F.; Opdenakker, G.; Sorokin, L.M. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 2006, 203, 1007–1019. [Google Scholar] [CrossRef]
- Backstrom, J.R.; Lim, G.P.; Cullen, M.J.; Tokes, Z.A. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading amyloid-beta peptide (1–40). J. Neurosci. 1996, 16, 7910–7919. [Google Scholar]
- Yan, P.; Hu, X.; Song, H.; Yin, K.; Bateman, R.J.; Cirrito, J.R.; Xiao, Q.; Hsu, F.F.; Turk, J.W.; Xu, J.; Hsu, C.Y.; Holtzman, D.M.; Lee, J.M. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J. Biol. Chem. 2006, 281, 24566–24574. [Google Scholar] [CrossRef]
- Tortorella, M.D.; Arner, E.C.; Hills, R.; Gormley, J.; Fok, K.; Pegg, L.; Munie, G.; Malfait, A.-M. ADAMTS-4 (aggreganase-1): N-terminal activation mechanisms. Arch. Biochem. Biophys. 2005, 444, 34–44. [Google Scholar] [CrossRef]
- Greenlee, K.J.; Corry, D.B.; Engler, D.A.; Matsunami, R.K.; Tessier, P.; Cook, R.G.; Werb, Z.; Kheradmand, F. Proteomic identification of in vivo substrates from matrix metalloproteinase 2 and 9 reveals a mechanism for resolution of inflammation. J. Immunol. 2006, 177, 7312–7321. [Google Scholar]
- Van den Steen, P.E.; Proost, P.; Wuyts, A.; van Damme, J.; Opdenakker, G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4 and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 275, 34335–34343. [Google Scholar]
- Van den Steen, P.E.; Wuyts, A.; Husson, S.J.; Proost, P.; van Damme, J.; Opdenakker, G. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur. J. Biochem. 2003, 270, 3739–3749. [Google Scholar] [CrossRef]
- Cox, J.H.; Dean, R.A.; Roberts, C.R.; Overall, C.M. Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. J. Biol. Chem. 2008, 283, 19389–19399. [Google Scholar] [CrossRef]
- Jin, F.; Zhai, Q.; Qui, L.; Meng, H.; Zou, D.; Wang, Y.; Li, Q.; Yu, Z.; Han, J.; Li, Q.; et al. Degradation of BM SDF-1 by MMP-9: The role in G-CSF-induced hematopoietic stem/progenitor cell mobilization. Bone Marrow Transplant. 2008, 42, 581–588. [Google Scholar] [CrossRef]
- Ruiz, S.; Henschen-Edman, A.H.; Nagase, H.; Tenner, A.J. Digestion of C1q collagen like domains by MMPs-1, -2, -3, and -9 further defines the sequence involved in the stimulation of neutrophil superoxide production. J. Leukoc. Biol. 1999, 66, 416–422. [Google Scholar]
- Butler, G.S.; Dean, R.A.; Tam, E.M.; Overall, C.M. Pharmacoproteomics of a metalloproteinase hydroxamates inhibitor in breast cancer cells: Dynamics of membrane type 1 matrix metalloproteinase-mediated protein shedding. Mol. Cell. Biol. 2008, 28, 4896–4914. [Google Scholar] [CrossRef]
- Patterson, B.C.; Sang, Q.A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 1997, 272, 28823–28825. [Google Scholar] [CrossRef]
- Farina, A.R.; Tacconelli, A.; Cappabianca, L.; Gulino, A.; Mackay, A.R. Inhibition of human MDA-MB-231 breast cancer invasion by matrix metalloproteinase 3 involves degradation of plasminogen. Eur. J. Biochem. 2002, 269, 4476–4483. [Google Scholar] [CrossRef]
- Bruno, M.A.; Cuello, C.A. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc. Natl. Acad. Sci. USA 2006, 103, 6735–6740. [Google Scholar] [CrossRef]
- Nelissen, I.; Martens, E.; van den Steen, P.E.; Proost, P.; Ronsse, I.; Opdenakker, G. Gelatinase B/Matrix metalloproteinase-9 cleaves interferon-b and is a target for immunotherapy. Brain 2003, 126, 1371–1381. [Google Scholar] [CrossRef]
- Takino, T.; Koshikawa, N.; Miyamori, H.; Tanaka, M.; Sasaki, T.; Okada, Y.; Seiki, M.; Sato, H. Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. Oncogene 2003, 4617–4626. [Google Scholar]
- Nubling, G.; Levin, J.; Brader, B.; Isreal, L.; Bitzel, K.; Lorenzi, S.; Giese, A. Limited cleavage of tau with matrix metalloproteinase gelatinase B/MMP-9, but not MMP-3, enhances tau oligomer formation. Exp. Neurol. 2012, 237, 470–476. [Google Scholar] [CrossRef]
- Lee, S.; Jilani, S.M.; Nikolova, G.V.; Carpizo, D.; Iruela-Arispe, M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumor. J. Cell. Biol. 2005, 169, 681–691. [Google Scholar] [CrossRef]
- Sato, H.; Kita, M.; Seiki, M. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J. Biol. Chem. 1993, 268, 23460–23468. [Google Scholar]
- Gum, R.; Lengyel, E.; Juarez, J.; Chen, J.H.; Seiki, M.; Boyd, D. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase 1-independent and requires multiple transcription factor binding sites including closely speced PEA3/ets and AP-1 sequences. J. Biol. Chem. 1996, 271, 10672–10680. [Google Scholar] [CrossRef]
- Han, Y.P.; Tuan, T.L.; Hughes, M.; Wu, H.; Garner, W.L. Transforming growth factor-beta-and tumor necrosis factor-alpha-mediated induction and activation of MMP-9 in human skin. J. Biol. Chem. 2001, 276, 22341–22350. [Google Scholar]
- Schwarzt, B.; Melnikova, V.O.; Tellez, C.; Mourad-Zeidan, A.; Blehm, K.; Zhao, Y.-J.; McCarty, M.; Adam, L.; Bar-Eli, M. Loss of AP-2a results in deregulation of E-caherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene 2007, 26, 4049–4058. [Google Scholar] [CrossRef]
- Farina, A.R.; Tacconelli, A.; Vacca, A.; Maroder, M.; Gulino, A.; Mackay, A.R. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SH-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differ. 1999, 10, 353–367. [Google Scholar]
- Farina, A.R.; Masciulli, M.-P.; Tacconelli, A.; Cappabianca, L.; de Santis, G.; Gulino, A.; Mackay, A.R. All-trans-retinoic acid induces nuclear factor κB activation and matrix metalloproteinase-9 expression and enhances basement membrane invasivity of differentiation-resistant human SK-N-BE 9N neuroblastoma cells. Cell Growth Differ. 2002, 13, 343–354. [Google Scholar]
- Hozumi, A.; Nishimura, Y.; Nishiuma, T.; Kotani, Y.; Yokoyama, M. Induction of MMP-9 in normal human bronchial epithelial cells by TNF-alpha via NF-kappa B-mediated pathway. Am. J. Physiol. Lung Cell Mol. Physiol. 2001, 281, L1444–L1452. [Google Scholar]
- Bond, M.; Chase, A.J.; Baker, A.H.; Newby, A.C. Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc. Res. 2001, 50, 556–565. [Google Scholar]
- Yokoo, T.; Kitamura, M. Dual regulation of Il-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappaB and AP-1. Am. J. Physiol. 1996, 270, F123–F130. [Google Scholar]
- Ricca, A.; Biroccio, A.; Del Bufalo, D.; Mackay, A.R.; Santoni, A.; Cipitelli, M. Bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7 (ADR) breast-cancer cells. Int. J. Cancer 2000, 86, 188–196. [Google Scholar] [CrossRef]
- Kumar, A.; Dhawan, S.; Mukhopadhyay, A.; Arrarwal, B.B. Human immunodeficiency virus-1-tat induces matrix metalloproteinase-9 in monocytes through protein tyrosine phosphatase-mediated activation of nuclear transcription factor NF-kappaB. FEBS Lett. 1999, 462, 140–144. [Google Scholar] [CrossRef]
- Yan, L.; Borregaard, N.; Kjeldsen, L.; Moses, M.A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 2001, 276, 37258–37265. [Google Scholar] [CrossRef]
- Bond, M.; Fabunmi, R.P.; Baker, A.H.; Newby, A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-kappa B. FEBS Lett. 1998, 435, 29–34. [Google Scholar] [CrossRef]
- Farina, A.R.; Cappabianca, L.; DeSantis, G.; di Ianni, N.; Ruggeri, P.; Ragone, M.; Merolla, S.; Tonissen, K.F.; Gulino, A.; Mackay, A.R. Thioredoxin stimulates MMP-9 expression, de-regulates the MMP-9/TIMP-1 equilibrium and promotes MMP-9 dependent invasion by human MDA-MB-231 breast cancer cells. FEBS Lett. 2011, 585, 3328–3336. [Google Scholar] [CrossRef]
- Himelstein, B.P.; Lee, E.J.; Sato, H.; Seike, M.; Muschel, R.J. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell lines. Oncogene 1997, 14, 1995–1998. [Google Scholar]
- Akgul, B.; Garcia-Escudero, R.; Ekechi, C.; Steger, G.; Navsaria, H.; Pfister, H.; Storey, A. he E2 protein of human papillomavirus type 8 increases the expression of matrix metalloproteinase-9 in human keratinocytes and organotypic skin cultures. Med. Microbiol. Immunol. 2011, 200, 127–135. [Google Scholar] [CrossRef]
- Akool, el-S.; Kleinert, H.; Hamada, F.M.; Abdelwahab, M.H.; Forstermann, U.; Pfeilschifter, J.; Eberhardt, W. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol. Cell. Biol. 2003, 23, 4901–4916. [Google Scholar] [CrossRef]
- Eberhardt, W.; Akool, el-S.; Rebhan, J.; Frank, S.; Beck, K.F.; Franzen, R.; Hamada, F.M.; Pfeilschifter, J. Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor alpha agonists is indirect and due to a NO-mediated reduction of mRNA stability. J. Biol. Chem. 2012, 277, 33518–33528. [Google Scholar]
- Jiang, Y.; Muschel, R.J. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res. 2002, 62, 1910–1914. [Google Scholar]
- Morini, M.; Mottolese, M.; Ferrari, N.; Ghiorzo, F.; Buglioni, S.; Mortarini, R.; Noonan, D.M.; Natali, P.G.; Albini, A. The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion and gelatinase B (MMP-9) activity. Int. J. Cancer 2000, 87, 336–342. [Google Scholar] [CrossRef]
- Sehgal, I.; Thompson, T.C. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cells. Mol. Biol. Cell 1999, 10, 407–416. [Google Scholar] [CrossRef]
- Thant, A.A.; Nawa, A.; Nikkawa, F.; Ichigotani, Y.; Zhang, Y.; Sein, T.T.; Amin, A.R.; Hamaguchi, M. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK-1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin. Exp. Metastasis 2000, 18, 423–428. [Google Scholar] [CrossRef]
- Iyer, V.; Pumiglia, K.; DiPersio, C.M. Alpha3beta1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: A novel mechanism of integrin-mediated MMP gene expression. J. Cell Sci. 2005, 118, 1185–1195. [Google Scholar] [CrossRef]
- Zhang, S.; Qi, L.; Li, M.; Zhang, D.; Xu, S.; Wang, N.; Sun, B.J. Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J. Exp. Clin. Cancer Res. 2008, 27, 62. [Google Scholar] [CrossRef]
- Farina, A.R.; Coppa, A.; Tiberio, A.; Tacconelli, A.; Turco, A.; Colletta, G.; Gulino, A.; Mackay, A.R. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int. J. Cancer 1998, 75, 721–730. [Google Scholar] [CrossRef]
- Festuccia, C.; Bologna, M.; Vicentini, C.; Tacconelli, A.; Miano, R.; Violini, S.; Mackay, A.R. Increased matrix metalloproteinase-9 secretion in short term tissue cultures of prostatic tumor cells. Int. J. Cancer 1996, 69, 386–393. [Google Scholar] [CrossRef]
- Shima, I.; Sasaguri, Y.; Kusukawa, J.; Nakano, R.; Yamana, H.; Fujita, H.; Kagegawa, T.; Morimatsu, M. Production of matrix metalloproteinase 9 (92 kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor. Br. J. Cancer 1993, 67, 721–727. [Google Scholar] [CrossRef]
- Price, T.J.; Wilson, H.M.; Haites, N.E. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur. J. Cancer 1996, 32A, 1977–1982. [Google Scholar] [CrossRef]
- Uchiyama, A.; Essner, R.; Dol, F.; Nguyen, T.; Ramming, K.P.; Nakamura, T.; Morton, D.L.; Hoon, D.S. Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas. J. Cell Biochem. 1996, 62, 443–453. [Google Scholar] [CrossRef]
- Horie, S.; Aruga, S.; Kawamata, H.; Okui, N.; Kakizoe, T.; Kitamura, T. Biological role of HGF/MET pathway in renal cell carcinoma. J. Urol. 1999, 161, 990–997. [Google Scholar] [CrossRef]
- Jiang, Y.; Xu, W.; Lu, J.; He, F.; Yang, X. Invasiveness of hepatocellular carcinoma cell lines: Contribution of hepatocyte growth factor, c-met, and transcription factor Est-1. Biochem. Biophys. Res. Commun. 2001, 286, 1123–1130. [Google Scholar] [CrossRef]
- Harvey, P.; Clark, I.M.; Jaurand, M.C.; Warn, R.M.; Edwards, D.R. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br. J. Cancer 2000, 83, 1147–1153. [Google Scholar] [CrossRef]
- To, Y.; Dohi, M.; Matsumoto, K.; Tanaka, R.; Sato, A.; Nakagome, K.; Nakamura, T.; Yamamoto, K. A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line. Am. J. Resp. Cell. Mol. Biol. 2002, 27, 220–226. [Google Scholar] [CrossRef]
- Lee, K.H.; Hyun, M.S.; Kim, J.R. Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. Clin. Exp. Metastasis 2003, 20, 499–505. [Google Scholar] [CrossRef]
- Kurogi, T.; Nabeshima, K.; Kataoka, H.; Okada, Y.; Koono, M. Stimulation of gelatinase B and tissue inhibitor of metalloproteinase (TIMP) production in co-culture of human osteosarcoma cells and human fibroblasts: Gelatinase B production was stimulated via up-regulation of fibroblast growth factor (FGF) receptor. Int. J. Cancer 1996, 66, 82–90. [Google Scholar] [CrossRef]
- Miyake, H.; Yoshimura, K.; Hara, I.; Eto, H.; Arakawa, S.; Kamidono, S. Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J. Urol. 1997, 157, 2351–2355. [Google Scholar] [CrossRef]
- Hazan, R.B.; Phillips, G.R.; Qiao, R.F.; Norton, L.; Aaronson, S.A. Exogenous expression of N-Cadherin in breast cancer cells induces cell migration, invasion and metastasis. J. Cell Biol. 2000, 148, 779–790. [Google Scholar] [CrossRef]
- Suyama, K.; Shapiro, I.; Guttman, M.; Hazan, R.B. A signalling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002, 2, 301–314. [Google Scholar]
- Sehgal, G.; Hua, J.; Bernhard, E.J.; Sehgal, I.; Thompson, T.C.; Muschel, R.J. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am. J. Pathol. 1998, 152, 591–596. [Google Scholar]
- Siddiqui, F.A.; Siddiqui, T.F.; Francis, J.L. Haemoglobin induces the production and release of matrix metalloproteinase-9 from human malignant cells. Blood Coagul. Fibrinolysis 2003, 14, 449–455. [Google Scholar] [CrossRef]
- Masure, S.; Proost, P.; van Damme, J.; Opdenakker, G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur. J. Biochem. 1991, 198, 391–398. [Google Scholar] [CrossRef]
- Rehman, A.A.; Ahsan, H.; Kahn, F.H. α-2-Macroglobulin: A physiological guardian. J. Cell. Physiol. 2013, 228, 1665–1675. [Google Scholar] [CrossRef]
- Gomez, D.E.; Alonso, D.F.; Yoshiji, H.; Thorgeirsson, U.P. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur. J. Cell Biol. 1997, 74, 111–122. [Google Scholar]
- Murphy, G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011, 12, 233. [Google Scholar] [CrossRef]
- Roeb, E.; Schleinkofer, K.; Kernebeck, T.; Potsch, S.; Jensen, B.; Behrmann, I.; Matern, S.; Grotzinger, J. The matrix metalloproteinase-9 (mmp-9) hemopexin domain is a novel gelatin-binding domain and acts as an antagonist. J. Biol. Chem. 2002, 277, 50326–50332. [Google Scholar] [CrossRef]
- Farina, A.R.; Tacconelli, A.; Cappabianca, L.; Masciulli, M.P.; Holmgren, A.; Beckett, G.J.; Gulino, A.; Mackay, A.R. Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion. Eur. J. Biochem. 2001, 268, 405–413. [Google Scholar] [CrossRef]
- Hahn-Dantona, E.; Ruiz, J.F.; Bornstein, P.; Strickland, D.K. The low-density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. J. Biol. Chem. 2001, 276, 15498–15503. [Google Scholar]
- Triebel, S.; Blaser, J.; Reinke, H.; Tschesche, H. A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 1992, 314, 386–388. [Google Scholar] [CrossRef]
- Chakraborty, S.; Kaur, S.; Guha, S.; Batra, S.K. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta 2012, 1826, 129–169. [Google Scholar]
- Ardi, V.C.; Kupriyanova, T.A.; Deryugina, E.L.; Quigley, J.P. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc. Natl. Acad. Sci. USA 2007, 104, 20262–20267. [Google Scholar] [CrossRef]
- Ardi, V.C.; van den Steen, P.E.; Opdenakker, G.; Schweighofer, B.; Deryugina, E.I.; Quigley, J.P. Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J. Biol. Chem. 2009, 284, 25854–25866. [Google Scholar]
- Huang, S.; van Arsdall, M.; Tedjarati, S.; McCarty, M.; Wu, W.; Langley, R.; Fidler, I.J. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. 2002, 94, 1134–1142. [Google Scholar] [CrossRef]
- O’Grady, A.; Dunne, C.; O’Kelly, P.; Murphy, G.M.; Leader, M.; Kay, E. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: Implications for tumour progression. Histopathology 2008, 51, 793–804. [Google Scholar]
- Heissenberg, M.C.; Gorogh, T.; Lippert, B.M.; Werner, J.A. Metalloproteinases and their inhibitors in squamous cell carcinoma of the hypopharynx: Indicators of individual tumor aggressiveness. Otolaryngol. Pol. 1998, 52, 521–526. [Google Scholar]
- Roeb, E.; Dietrich, C.G.; Winograd, R.; Arndt, M.; Breuer, B.; Fass, J.; Schumpelick, V.; Matern, S. Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer 2001, 92, 2680–2691. [Google Scholar] [CrossRef]
- Asai, M.; Kato, M.; Asai, N.; Iwashita, T.; Murakami, H.; Kawai, K.; Nakashima, I.; Takahashi, M. Differential regulation of MMP-9 and TIMP-2 expression in malignant melanoma developed in metallothionin/RET transgenic mice. Jpn. J. Cancer Res. 1999, 90, 86–92. [Google Scholar] [CrossRef]
- Dong, Z.; Nemeth, J.A.; Cher, M.L.; Palmer, K.C.; Bright, R.C.; Fridman, R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int. J. Cancer 2001, 93, 507–515. [Google Scholar] [CrossRef]
- Schonherr, E.; Schaefer, L.; O’Connel, B.C.; Kresse, H. Matrix metalloproteinase expression by endothelial cells in collagen lattices changes during co-culture with fibroblasts and upon induction of decorin expression. J. Cell Physiol. 2001, 187, 37–47. [Google Scholar] [CrossRef]
- Smola-Hess, S.; Schnitzler, R.; Hadaschik, D.; Smola, H.; Mauch, C.; Krieg, T.; Pfister, H. CD40L induces matrix metalloproteinase-9 but not tissue inhibitor of metalloproteinase-1 in cervical carcinoma cells: Imbalance between NF-kappaB and STAT3 activation. Exp. Cell Res. 2001, 267, 205–215. [Google Scholar] [CrossRef]
- O-charoenrat, P.; Rhys-Evans, P.; Court, W.J.; Box, G.M.; Eccles, S.A. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands. Clin. Exp. Metastasis 1999, 17, 631–639. [Google Scholar] [CrossRef]
- Chang, X.Z.; Li, D.Q.; Hou, Y.F.; Wu, J.; Lu, J.S.; Di, G.H.; Jin, W.; Ou, Z.L.; Shen, Z.Z.; Shao, Z.M. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res. 2007, 9, R76. [Google Scholar] [CrossRef]
- Kim, J.H.; Kim, J.H.; Cho, C.S.; Jun, H.O.; Kim, D.H.; Yu, Y.S.; Kim, K.-W. Differential roles of matrix metalloproteinase-9 and -2, depending on proliferation or differentiation of retinoblastoma cells. Invest. Opthalmol. Vis. Sci. 2010, 51, 1783–1788. [Google Scholar] [CrossRef]
- Yu, G.; Wang, X.; Wu, T.; Zhu, J.; Huang, S.; Wan, Y.; Tang, J. MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion. Mol. Cell. Biochem. 2013, 380, 239–247. [Google Scholar] [CrossRef]
- Li, S.; Guo, J.; Wu, J.; Sun, Z.; Han, M.; Shan, S.W.; Deng, Z.; Yang, B.B.; Weisel, R.D.; Li, R.K. miR-17 targets tissue inhibitor of metalloproteinase-1 and 2 to modulate cardiac matrix remodelling. FASEB J. 2013, 27, 4254–4265. [Google Scholar] [CrossRef]
- Oh, J.H.; Chung, A.S.; Steinbrenner, H.; Sies, H.; Brenneisen, P. Thioredoxin secreted upon ultraviolet A irradiation modulates the activities of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in human dermal fibroblasts. Arch. Biochem. Biophys. 2004, 423, 218–226. [Google Scholar] [CrossRef]
- Shabani, F.; McNeil, J.; Tippett, L. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCl), is suppressed by anti-rheumatic drugs. Free Radic. Res. 1998, 28, 115–123. [Google Scholar] [CrossRef]
- Wang, Y.; Rosen, H.; Madtes, D.K.; Shao, B.; Martin, T.R.; Heinecke, J.W.; Fu, X. Myeloperoxidase inactivates TIMP-1 by oxidising its N-terminal Cystein residue. J. Biol. Chem. 2007, 282, 31826–31834. [Google Scholar] [CrossRef]
- Thompson, E.W.; Mackay, A.R. Review of: Opposing effects for specific TIMPs in breast cancer. Breast Cancer Online 2005, 8, e5. [Google Scholar]
- Okada, Y.; Watanabe, S.; Nakanishi, I.; Kishi, J.; Hayakawa, T.; Watorek, W.; Travis, J.; Nagase, H. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett. 1988, 229, 157–160. [Google Scholar] [CrossRef]
- Ferry, G.; Lonchampt, M.; Pennel, L.; de Nanteil, G.; Canet, E.; Tucker, G.C. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett. 1997, 402, 111–115. [Google Scholar] [CrossRef]
- Itkonen, O. Human trypsinogens in the pancreas and in cancer. Scand. J. Clin. Lab. Invest. 2010, 70, 136–143. [Google Scholar] [CrossRef]
- Tsai, J.R.; Wang, H.M.; Liu, P.L.; Chen, Y.H.; Yang, M.C.; Chou, S.H.; Cheng, Y.J.; Yin, W.H.; Hwang, J.J.; Chong, I.W. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. Cell. Oncol. 2012, 35, 461–471. [Google Scholar] [CrossRef]
- Yeghiazaryan, M.; Zybura-Broda, K.; Cabaj, A.; Wlodarczyk, J.; Slaeinska, U.; Rylski, M.; Wilczynski, G.M. Fine-structural distribution of MMP-2 and MMP-9 activities in the rat skeletal muscle upon training: A study of high resolution in situ zymography. Histochem. Cell Biol. 2012, 138, 75–87. [Google Scholar] [CrossRef]
- Yang, Y.; Candelario-Jalil, E.; Thompson, J.F.; Cuadrado, E.; Estrada, E.Y.; Rosell, A.; Montaner, J.; Rosenberg, G.A. Increased intranuclear metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J. Neurochem. 2010, 112, 134–149. [Google Scholar] [CrossRef]
- Kwan, J.A.; Schulze, C.J.; Wang, W.; Leon, H.; Sariahmetoglu, M.; Sung, M.; Sawicka, J.; Simms, D.E.; Sawicki, G.; Schulz, R. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 2004, 18, 690–692. [Google Scholar]
- Hill, J.W.; Poddar, R.; Thompson, J.F.; Rosenberg, G.A.; Yang, Y. Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons. Neuroscience 2012, 18, 277–290. [Google Scholar]
- Mannello, F.; Luchetti, F.; Falcieri, E.; Papa, S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 2005, 10, 19–24. [Google Scholar]
- Monferran, S.; Paupert, J.; Dauvillier, S.; Salles, B.; Muller, C. The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J. 2004, 23, 3758–3768. [Google Scholar] [CrossRef]
- Sans-Fons, G.M.; Sole, S.; Sanfeliu, C.; Planas, A.M. Matrix metalloproteinase-9 and cell division in neuroblastoma cells and bone marrow macrophages. Am. J. Pathol. 2010, 177, 2870–2885. [Google Scholar] [CrossRef]
- Zhao, W.J.; Zhang, W.; Li, G.L.; Cui, Y.; Shi, Z.F.; Yuan, F. Differential expression of MMP-9 and AQP4 in human glioma samples. Folia Neuropathol. 2012, 50, 176–186. [Google Scholar]
- Moran, A.; Iniesta, P.; de Juan, C.; Gonzales-Quevedo, R.; Sanchez-Pernaute, A.; Diaz-Rubio, E.; Ramon y Cajal, S.; Torres, A.; Balibrea, J.L.; Benito, M. Stromelysin-1 promoter mutations impair gelatinase B activation in high microsatellite instability sporadic colorectal tumors. Cancer Res. 2002, 62, 3855–3860. [Google Scholar]
- Moran, A.; Iniesta, P.; de Juan, C.; Garcia-Aranda, C.; Benito, M. Impairment of stromelysin-1 transcriptional activity by promoter mutations in high microsatellite instability colorectal tumors. Cancer Res. 2005, 65, 3811–3814. [Google Scholar] [CrossRef]
- Thiefin, G.; Dupont, A.; Guillou, P.J.; Vitry, F.; Bouche, O.; Yaziji, N.; Lagarde, S.; Maquart, F.X.; Palot, J.P.; Hornebeck, W.; et al. Beneficial influence of microsatellite instability on gelatinase-tissue inhibitors of metalloproteinase balance in colorectal cancer. Anticancer Res. 2007, 27, 583–588. [Google Scholar]
- Sinnamon, M.J.; Carter, K.J.; Fingleton, B.; Matrisian, L.M. Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse. Int. J. Exp. Pathol. 2008, 89, 466–475. [Google Scholar] [CrossRef]
- Opdenakker, G.; van den Steen, P.E.; Dubois, B.; Nielssen, I.; van Coillie, E.; Masure, S.; Proost, P.; van Damme, J. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 2001, 69, 851–859. [Google Scholar]
- Radisky, D.C.; Levy, D.D.; Litllepage, L.E.; Liu, H.; Nelson, C.M.; Fata, J.E.; Leake, D.; Godden, E.L.; Albertson, D.G.; Nieto, M.A.; et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005, 436, 123–127. [Google Scholar] [CrossRef]
- Samper, E.; Nicholls, D.G.; Melov, S. Mitochondrial oxidative stress causes chromosomal instability of mouse embryonic fibroblasts. Aging Cell 2003, 2, 277–285. [Google Scholar] [CrossRef]
- Thieringer, F.R.; Maass, T.; Anthon, B.; Meyer, E.; Schirmacher, P.; Longerich, T.; Galle, P.R.; Kanzler, S.; Teufel, A. Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular cancer. Mol. Carcinog. 2012, 51, 439–448. [Google Scholar] [CrossRef]
- Fatunmbi, M.; Shelton, J.; Aronica, S.M. gelatinase B/MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelia cells. Breast Cancer Res. Treat. 2012, 135, 519–530. [Google Scholar] [CrossRef]
- Ponnala, S.; Veeravalli, K.K.; Chetty, C.; Dinh, D.H.; Rao, J.S. Regulation of DNA repair mechanism in human glioma xenograft cells both in vitro and in vivo in nude mice. PLoS One 2011, 6, e26191. [Google Scholar]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef]
- Colotta, F.; Allavena, P.; Sica, A.; Garlanda, C.; Mantovani, A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009, 30, 1073–1081. [Google Scholar] [CrossRef]
- Bergers, G.; Brekken, R.; McMahon, G.; Vu, T.H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell. Biol. 2000, 2, 737–744. [Google Scholar] [CrossRef]
- Belotti, D.; Paganoni, P.; Manetti, L.; Garofalo, A.; Marchini, S.; Taraboletti, G.; Giavazzi, R. Matrix metalloproteinases (MMP-9 and MMP-2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: Implications for ascites formation. Cancer Res. 2003, 63, 5224–5229. [Google Scholar]
- Mott, J.D.; Werb, Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004, 16, 558–564. [Google Scholar] [CrossRef]
- Brauer, P.R. MMPs—Role in cardiovascular development and disease. Front Biosci. 2006, 11, 447–478. [Google Scholar] [CrossRef]
- Rorive, S.; Berton, A.; D’haene, N.; Takacs, C.N.; Debeir, O.; Decaestecker, C.; Salmon, I. Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas. Glia 2008, 56, 1679–1690. [Google Scholar] [CrossRef]
- Alferez, D.; Wilkinson, R.W.; Watkins, J.; Poulsom, R.; Mandir, N.; Wedge, S.R.; Pyrah, I.T.; Smith, N.R.; Jackson, L.; Ryan, A.J.; et al. Dual inhibition of VEGFR and EGFR signalling reduces the incidence and size of intestinal adenomas in Apc(min/+) mice. Mol. Cancer Ther. 2008, 7, 590–598. [Google Scholar] [CrossRef]
- Ingraham, C.A.; Park, G.C.; Makarenkova, H.P.; Crossin, K.L. Matrix metalloproteinase (MMP)-9 induced by Wnt signalling increases the proliferation and migration of embryonic neural stem cells at low O2 levels. J. Biol. Chem. 2011, 286, 17649–17657. [Google Scholar]
- Aguilar-Gallardo, C.; Simon, C. Cells, stem cells and cancer stem cells. Semin. Reprod. Med. 2013, 31, 5–13. [Google Scholar] [CrossRef]
- Beck, B.; Blanpain, C. Unravelling cancer stem cell potential. Nat. Rev. Cancer 2013, 13, 727–738. [Google Scholar] [CrossRef]
- Santamaria-Martinez, A.; Huelsken, J. The niche under siege: Novel targets for metastasis therapy. J. Intern. Med. 2013, 274, 127–136. [Google Scholar] [CrossRef]
- Seidel, S.; Garvalov, B.K.; Wirta, W.; von Stechow, L.; Schanzer, A.; Meletis, K.; Wolter, M.; Sommerlad, D.; Henze, A.T.; Nister, M.; et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010, 133, 983–995. [Google Scholar] [CrossRef]
- Wang, J.; Loberg, R.; Taichman, R.S. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Met. Rev. 2006, 25, 573–587. [Google Scholar]
- Wels, J.; Kaplan, R.N.; Rafii, S.; Lyden, D. Migratory neighbors and distant invaders: Tumor-associated niche cells. Genes Dev. 2008, 22, 559–574. [Google Scholar] [CrossRef]
- Chiang, A.C.; Massague, J. Molecular basis of metastasis. N. Engl. J. Med. 2008, 359, 2814–2823. [Google Scholar] [CrossRef]
- Van Amerongen, R.; Nusse, R. Towards an integrated view of Wnt signalling in development. Development 2009, 136, 3205–3214. [Google Scholar] [CrossRef]
- Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442–454. [Google Scholar] [CrossRef]
- Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 2011, 414, 105–111. [Google Scholar]
- Brabletz, T.; Hlubek, F.; Spaderna, S.; Schmalhofer, O.; Hiendlmeyer, E.; Jung, A.; Kirchner, T. Invasion and metastasis in colorectal cancer: Epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta catenin. Cells Tissues Organs 2005, 179, 56–65. [Google Scholar] [CrossRef]
- Pardal, R.; Clarke, M.F.; Morrison, S.J. Applying principles of stem-cell biology to cancer. Nat. Rev. Cancer 2003, 3, 895–902. [Google Scholar] [CrossRef]
- Margetts, P.J. Twist: A new player in the epithelial-mesenchymal transition of the peritoneal mesothelial cells. Nephrol. Dial. Transplant. 2012, 27, 3978–3981. [Google Scholar] [CrossRef]
- Lin, C.Y.; Tsai, P.H.; Kandaswami, C.C.; Lee, P.P.; Huang, C.J.; Lee, M.T. Matrix metalloproteinase-9 cooperates with transcription factor snail to induce epithelial-mesenchymal transition. Cancer Sci. 2011, 102, 815–827. [Google Scholar] [CrossRef]
- Asuthkar, S.; Nalla, A.K.; Gondi, G.S.; Dinh, D.H.; Gujrati, M.; Mohanam, S.; Rao, J.S. Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT. Neuro. Oncol. 2011, 13, 1059–1073. [Google Scholar] [CrossRef]
- Gao, X.H.; Yang, X.Q.; Wang, B.C.; Liu, S.P.; Wang, F.B. Overexpression of twist and matrix metalloproteinase-9 with metastasis and prognosis in gastric cancer. Asian Pac. J. Cancer Prev. 2013, 14, 5055–5060. [Google Scholar]
- Zhao, J.; Guan, J.L. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009, 28, 35–49. [Google Scholar] [CrossRef]
- Li, J.; Li, F.; Wang, H.; Wang, X.; Jiang, Y.; Li, D. Wortmannin reduces metastasis and angiogenesis of human breast cancer cells via nuclear factor-kappaB-dependent matrix metalloproteinase-9 and interleukin-8 pathways. J. Int. Med. Res. 2012, 40, 867–876. [Google Scholar] [CrossRef]
- Zhao, J.; Guan, J.L. Focal adhesion kinase and its signalling pathways in cell migration and angiogenesis. Adv. Drug Deliv. Rev. 2011, 63, 610–615. [Google Scholar] [CrossRef]
- Yoo, Y.A.; Kang, M.H.; Lee, H.J.; Kim, B.H.; Park, J.K.; Kim, H.K.; Kim, J.S.; Oh, S.C. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011, 71, 7061–7070. [Google Scholar] [CrossRef]
- Opdenakker, G.; van den Steen, P.E.; van Damme, J. Gelatinase B: A tuner and amplifier of immune functions. Trends Immunol. 2001, 22, 571–579. [Google Scholar] [CrossRef]
- Chakrabarti, S.; Patel, K.D. Regulation of matrix metalloproteinase release from IL-8-stimulated human neutrophils. J. Leukoc. Biol. 2005, 78, 279–288. [Google Scholar] [CrossRef]
- Chinni, S.R.; Sivalogan, S.; Dong, Z.; Filho, J.C.; Deng, X.; Bonfil, R.D.; Cher, M.L. CXCL12/CXCR4 signaling activates Akt and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate 2006, 66, 32–48. [Google Scholar] [CrossRef]
- Kwak, Y.E.; Jeon, N.K.; Kim, J.; Lee, E.J. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Ann. NY Acad. Sci. 2007, 1095, 99–112. [Google Scholar] [CrossRef]
- Ishizaki, T.; Katsumata, K.; Tsuchida, A.; Wada, T.; Mori, Y.; Hisada, M.; Kawakita, H.; Aoki, T. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of gelatinase B/MMP-9 activity. Int. J. Mol. Med. 2006, 17, 357–362. [Google Scholar]
- Kim, Y.H.; Kwon, H.J.; Kim, D.S. Matrix metalloproteinase 9 (MMP-9)-dependent processing of Big-h3 protein regulates cell migration, invasion, and adhesion. J. Biol. Chem. 2012, 287, 38957–38969. [Google Scholar] [CrossRef]
- Leifer, K.S.; Svensson, S.; Abrahamsson, A.; Bendrick, C.; Robertson, J.; Gauldie, J.; Olsson, A.-K.; Dabrosin, C. Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J. Immunol. 2013, 190, 4420–4430. [Google Scholar] [CrossRef]
- Farnsworth, R.H.; Lackmann, M.; Achen, M.G.; Stacker, S.A. Vascular remodelling in cancer. Oncogene 2013. [Google Scholar] [CrossRef]
- Van Hinsbergh, V.W.; Engelse, M.A.; Quax, P.H. Pericellular proteases in angiogenesis and vasculogenesis. Aterioscler. Thromb. Vasc. Biol. 2006, 26, 716–728. [Google Scholar] [CrossRef]
- Joyce, J.A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005, 7, 513–520. [Google Scholar] [CrossRef]
- Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3, 401–410. [Google Scholar] [CrossRef]
- Coussens, L.M.; Tinkle, C.L.; Hanahan, D.; Web, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103, 481–490. [Google Scholar] [CrossRef]
- Heissig, B.; Werb, Z.; Rafii, S.; Hattori, K. Role of c-kit/Kit ligand signalling in regulating vasculogenesis. Thromb. Haemost. 2003, 90, 570–576. [Google Scholar]
- Mira, E.; Lacalle, R.A.; Buesa, J.M.; de Buitrago, G.G.; Jimenez-Baranda, S.; Gòmez-Moutòn, C.; Mrtinaz, A.C.; Manes, S. Secreted MMP-9 promotes angiogenesis more efficiently than constitutive active MMP-9 bound to the tumour cell surface. J. Cell Sci. 2004, 117, 1847–1857. [Google Scholar] [CrossRef]
- Gao, D.; Nolan, D.; McDonnell, K.; Vahdat, L.; Benezra, R.; Attorki, N.; Mittal, V. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim. Biophys. Acta 2009, 1796, 33–40. [Google Scholar]
- Giraudo, E.; Inoue, M.; Hanahan, D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical angiogenesis. J. Clin. Investig. 2004, 114, 623–633. [Google Scholar]
- Nosawa, H.; Chiu, C.; Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 12493–12498. [Google Scholar] [CrossRef]
- Melani, C.; Sangaletti, S.; Barazzetta, F.M.; Werb, Z.; Colombo, M.P. Amino-bisphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007, 67, 11438–11446. [Google Scholar] [CrossRef]
- Hagemann, T.; Robinson, S.C.; Schultz, M.; Trumper, L.; Balkwill, F.R.; Binder, C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteinases. Carcinogenesis 2004, 25, 1543–1549. [Google Scholar] [CrossRef]
- Morales, J.K.; Kmeiciak, M.; Knutson, K.L.; Bear, H.D.; Manjili, M.H. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 2010, 123, 39–49. [Google Scholar]
- Marigo, I.; Dolcetti, L.; Serafini, P.; Zanovello, P.; Bronte, V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 2008, 222, 162–179. [Google Scholar] [CrossRef]
- Gabrilovich, D.I.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9, 162–174. [Google Scholar] [CrossRef]
- Urbich, C.; Dimmeler, S. Endothelial progenitor cells: Characterisation and role in vascular biology. Circ. Res. 2004, 95, 343–353. [Google Scholar] [CrossRef]
- Rafii, S.; Lyden, D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 2003, 9, 702–712. [Google Scholar] [CrossRef]
- Inoue, T.; Taguchi, I.; Abe, S.; Toyoda, S.; Nakajima, K.; Sakuma, M.; Node, K. Activation of matrix metalloproteinase-9 is associated with mobilization of bone marrow-derived cells after coronary stent implantation. Int. J. Cardiol. 2011, 152, 332–336. [Google Scholar] [CrossRef]
- Inoue, T.; Sata, M.; Hikichi, Y.; Sohma, R.; Fukuda, D.; Uchida, T.; Shimizu, M.; Komoda, H.; Node, K. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: Impact on restenosis. Circulation 2007, 115, 553–561. [Google Scholar] [CrossRef]
- Jodele, S.; Chantrain, C.F.; Blavier, L.; Lutzko, C.; Crooks, G.M.; Shimada, H.; Coussens, L.M.; DeClerck, Y.A. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res. 2005, 65, 3200–3208. [Google Scholar]
- Tacconelli, A.; Farina, A.R.; Cappabianca, L.; de Santis, G.; Tessitore, A.; Vetuschi, A.; Sferra, R.; Rucci, N.; Argenti, B.; Screpanti, I.; et al. TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 2004, 6, 347–360. [Google Scholar] [CrossRef]
- Chantrain, C.F.; Shimada, H.; Jodele, S.; Groshen, S.; Ye, W.; Shalinsky, D.R.; Werb, Z.; Coussens, L.M.; DeClerck, Y.A. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004, 64, 1675–1686. [Google Scholar] [CrossRef]
- Nielsen, B.S.; Sehested, M.; Kjeldsen, L.; Borregaard, N.; Rygaard, J.; Dano, K. Expression of matrix metalloproteinase-9 in vascular pericytes in human breast cancer. Lab. Invest. 1997, 77, 345–355. [Google Scholar]
- Vu, T.H.; Shipley, J.M.; Bergers, G.; Berger, J.E.; Helms, J.A.; Hanahan, D.; Shapiro, S.D.; Senior, R.M.; Werb, Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93, 411–422. [Google Scholar] [CrossRef]
- Ahn, G.O.; Brown, J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: Role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13, 195–205. [Google Scholar]
- Johnson, C.; Sung, H.J.; Lessner, S.M.; Fini, M.E.; Galis, Z.S. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: Potential role in capillary branching. Circ. Res. 2004, 94, 262–268. [Google Scholar] [CrossRef]
- Shekhar, M.P.; Werdell, J.; Santner, S.J.; Pauley, R.J.; Tait, L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: Implications for tumor development and progression. Cancer Res. 2001, 61, 1320–1326. [Google Scholar]
- Nakamura, T.; Kuwai, T.; Kim, J.S.; Fan, D.; Kim, S.J.; Fidler, I.J. Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia 2007, 9, 979–986. [Google Scholar] [CrossRef]
- He, J.Z.; Quan, A.; Xu, Y.; Teoh, H.; Wang, G.; Fish, J.E.; Steer, B.M.; Itohara, S.; Marsden, P.A.; Davidge, S.T.; et al. Induction of matrix metalloproteinase-2 enhances systemic arterial contraction after hypoxia. Am. J. Physiol. 2007, 292, 684–693. [Google Scholar]
- Nakano, D.; Hyashi, T.; Tazawa, N.; Yamashita, C.; Inamoto, S.; Okuda, N.; Mori, T.; Sohmiya, K.; Kitaura, Y.; Okada, Y.; et al. Chronic hypoxia accelerates the progression of atherosclerosis in apoliprotein E-knockout mice. Hypertens. Res. 2005, 28, 837–845. [Google Scholar] [CrossRef]
- Zalba, G.; Fortuno, A.; Orbe, J.; San Jose, G.; Moreno, M.U.; Belzunce, M.; Rodriguez, J.A.; Beloqui, O.; Paramo, J.A.; Diez, J. Phagocytic NADPH oxidase-dependent superoxide production stimulates metalloproteinase-9: Implications for human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 587–593. [Google Scholar] [CrossRef]
- Jadhav, U.; Chigurupati, S.; Lakka, S.S.; Mohanam, S. Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int. J. Oncol. 2004, 25, 1407–1414. [Google Scholar]
- Tallant, C.; Marrero, A.; Gomis-Ruth, F.X. Matrix metalloproteinases: Fold and function of their catalytic domains. Biochim. Biophys. Acta 2010, 1803, 20–28. [Google Scholar] [CrossRef]
- Li, H.; Liang, J.; Castrillon, D.H.; DePinho, R.A.; Olson, E.N.; Liu, Z.P. FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene expression. Mol. Cell. Biol. 2007, 27, 2676–2686. [Google Scholar] [CrossRef]
- Chandrasekar, B.; Mummidi, S.; Mahimainathan, L.; Patel, D.N.; Bailey, S.R.; Imam, S.Z.; Greene, W.C.; Valente, A.J. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J. Biol. Chem. 2006, 281, 15099–15109. [Google Scholar] [CrossRef]
- Cheng, G.; Wei, L.; Xiurong, W.; Xiangzhen, L.; Shiguang, Z.; Songbin, F. IL-17 stimulates migration of carotid artery smooth muscle cells in an MMP-9 dependent manner via p38 MAPK and ERK1/2-dependent NF-KappaB and AP-1 activation. Cell. Mol. Neurobiol. 2009, 29, 1161–1168. [Google Scholar] [CrossRef]
- Galis, Z.S.; Johnson, C.; Godin, D.; Magid, R.; Shipley, J.M.; Senior, R.M.; Ivan, E. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodelling. Circ. Res. 2002, 91, 852–859. [Google Scholar] [CrossRef]
- Jenkins, G.M.; Crow, M.T.; Bilato, C.; Gluzband, Y.; Ryu, W.S.; Li, Z.; Stetler-Stevenson, W.; Nater, C.; Froehlich, J.P.; Lakatta, E.G.; et al. Increased expression of membrane type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation 1998, 97, 82–90. [Google Scholar] [CrossRef]
- Xu, J.; Rodriguez, D.; Petitclerc, E.; Kim, J.J.; Hangai, M.; Moon, Y.S.; Davis, G.E.; Brooks, P.C. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 2001, 154, 1069–1080. [Google Scholar] [CrossRef]
- Hamano, Y.; Zeisberg, M.; Sugimoto, H.; Lively, J.C.; Maeshima, Y.; Yang, C.; Hynes, R.O.; Werb, Z.; Sudhakar, A.; Kalluri, R. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003, 3, 589–601. [Google Scholar] [CrossRef]
- Wahl, M.L.; Kenan, D.J.; Gonzalez-Gronow, M.; Pizzo, S.V. Angiostatin’s molecular mechanism: Aspects of specificity and regulation elucidated. J. Cell. Biochem. 2005, 96, 242–261. [Google Scholar] [CrossRef]
- Kalhuri, R. Basement membranes: Structure, assembly and role in tumor angiogenesis. Nat. Rev. Cancer 2003, 3, 422–433. [Google Scholar] [CrossRef]
- Sudhakar, A.; Sugimoto, H.; Yang, C.; Lively, J.; Zeisberg, M.; Kalluri, R. Human tumstatin and human endostatin exhibit distinct anti-angiogenic activities mediated by alpha V beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA 2003, 100, 4766–4771. [Google Scholar]
- Kim, Y.M.; Jang, J.W.; Lee, O.H.; Yeon, J.; Choi, E.Y.; Kim, K.W.; Lee, S.T.; Kwon, Y.G. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 2000, 60, 5410–5413. [Google Scholar]
- Nyberg, P.; Heikkila, P.; Sorsa, T.; Luostarinen, J.; Heljasvaara, R.; Stenman, U.H.; Pihlajaniemi, T.; Salo, T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloproteinase-2, -9, and -13. J. Biol. Chem. 2003, 278, 22404–22411. [Google Scholar] [CrossRef]
- Guan, K.P.; Ye, H.Y.; Yan, Z.; Wang, Y.; Huo, S.K. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003, 61, 719–723. [Google Scholar] [CrossRef]
- Ezhilarasan, R.; Jadhav, U.; Mohaman, I.; Rao, J.S.; Gujrati, M.; Mohaman, S. The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int. J. Cancer 2009, 124, 306–315. [Google Scholar] [CrossRef]
- Qian, X.; Wang, T.N.; Rothman, V.L.; Nicosia, R.F.; Tuszynski, G.P. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in epithelial cells. Exp. Cell Res. 1997, 235, 403–412. [Google Scholar] [CrossRef]
- Asuthkar, S.; Velpula, K.K.; Nalla, A.K.; Gogineni, V.R.; Gondi, C.S.; Rao, J.S. Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop on medulloblastoma cells. Oncogene 2013. [Google Scholar] [CrossRef]
- Wang, X.; Lee, S.O.; Xia, S.; Jiang, Q.; Luo, J.; Li, L.; Yeh, S.; Chang, C. Endothelial cells enhance prostate cancer metastasis via IL-6-androgen receptor-TGF-β-MMP-9 signals. Mol. Cancer Ther. 2013, 12, 1026–1037. [Google Scholar] [CrossRef]
- Loukovaara, S.; Robciuc, A.; Holopainen, J.M.; Lehti, K.; Pessi, T.; Liinamaa, J.; Kukkonen, K.T.; Jauhiainen, M.; Koli, K.; Keski-Oja, J.; et al. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ in diabetic eyes undergoing vitrectomy. Acta Opthalmol. 2013, 91, 531–539. [Google Scholar] [CrossRef]
- Hiratsuka, S.; Nakamura, K.; Iwai, S.; Murakami, M.; Itoh, T.; Kijima, H.; Shipley, J.M.; Senior, R.M.; Shibuya, M. MMP9 induction by vascular endothelial cell growth factor receptor-1 is involved in lung specific metastasis. Cancer Cell 2002, 2, 289–300. [Google Scholar]
- Wang, H.; Keiser, J.A. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1. Circ. Res. 1998, 83, 832–840. [Google Scholar] [CrossRef]
- Ghosh, S.; Basu, M.; Roy, S.S. ETS-1 protein regulates vascular endothelial cell growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J. Biol. Chem. 2012, 287, 15001–15015. [Google Scholar] [CrossRef]
- Christoffersson, G.; Vagesjo, E.; Vandooren, J.; Liden, M.; Massena, S.; Reinert, R.B.; Brissova, M.; Powers, A.C.; Opdenakker, G.; Phillipson, M. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood 2012, 120, 4653–4662. [Google Scholar] [CrossRef]
- Lungu, G.; Covaleda, L.; Mendes, O.; Martini-Stoica, H.; Stoica, G. FGF-1-induced matrix metalloproteinase-9 expression in breast cancer cells is mediated by increased activities of NF-kappaB and activating protein-1. Mol. Carcinogen. 2008, 47, 424–435. [Google Scholar] [CrossRef]
- Mohan, R.; Sivak, J.; Ashton, P.; Russo, L.A.; Pham, B.Q.; Kasahara, N.; Raizman, M.B.; Fini, E.M. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J. Biol. Chem. 2000, 275, 10405–10412. [Google Scholar]
- Tang, L.; Ma, X.; Tian, Q.; Cheng, Y.; Yao, H.; Liu, Z.; Qu, X.; Han, X. Inhibition of angiogenesis and invasion by DMBT is mediated by down regulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells. Food Chem. Toxicol. 2013, 56, 204–213. [Google Scholar] [CrossRef]
- Xu, Y.B.; Du, Q.H.; Zhang, M.Y.; Yun, P.; He, C.Y. Propofol suppresses proliferation, invasion and angiogenesis by down regulating ERK/VEGF/MMP-9 signaling in Eca-109 esophageal squamous cell carcinoma cells. Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 2486–2494. [Google Scholar]
- Gorantla, B.; Bhoopathi, P.; Chetty, C.; Gogineni, V.R.; Sailaja, G.S.; Gondi, C.S.; Rao, J.S. Notch signalling regulates tumor-induced angiogenesis in SPARC overexpressed neuroblastoma. Angiogenesis 2013, 16, 85–100. [Google Scholar] [CrossRef]
- Jia, W.; Gao, X.J.; Zhang, Z.X.; Zhang, G. S100A4 silencing suppresses proliferation, angiogenesis and invasion of thyroid cancer cells through down regulation of MMP-9 and VEGF. Eur. Rev. Med. Pharm. Sci. 2013, 17, 1495–1508. [Google Scholar]
- Yi, E.Y.; Kim, Y.J. Xylitol inhibits in vitro and in vivo angiogenesis by suppressing the NF-κB and Akt signalling pathways. Int. J. Oncol. 2013, 43, 315–320. [Google Scholar]
- Xu, J.; Zhu, D.; Sonoda, S.; He, S.; Spee, C.; Ryan, S.J.; Hinton, D.R. Over-expression of BMP4 inhibits choroidal neovascularization by modulating VEGF and MMP-9. Angiogenesis 2012, 15, 213–227. [Google Scholar] [CrossRef]
- Suboj, P.; Babykutty, S.; Valiyaparambil Gopi, D.R.; Nair, R.S.; Srinivas, P.; Gopala, S. Aloe emodin inhibits colon cancer cell migration/angiogenesis by down regulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-κB. Eur. J. Pharm. Sci. 2012, 45, 581–591. [Google Scholar] [CrossRef]
- Hendrix, M.J.C.; Seftor, E.A.; Meltzer, P.S.; Gardner, L.M.G.; Hess, A.R.; Kirschmann, D.A.; Schatteman, G.C.; Seftor, R.E.B. Expression and function of VE-cadherin in aggressive human melanoma cells: Role invasculogenic mimicry. Proc. Natl. Acad. Sci. USA 2001, 98, 8018–8023. [Google Scholar] [CrossRef]
- Karoum, A.; Mirshahi, P.; Faussat, A.-M.; Therwath, A.; Mirshahi, M.; Hatmi, M. Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expression. Mol. Cell. Pharmacol. 2012, 685, 1–7. [Google Scholar]
- Wong, S.Y.; Hynes, R.O. Lymphatic or hematogenous dissemination: How does a metastatic tumor cell decide? Cell Cycle 2006, 5, 812–817. [Google Scholar] [CrossRef]
- Christiansen, A.; Detmar, M. Lymphangiogenesis and cancer. Genes Cancer 2011, 2, 1146–1158. [Google Scholar] [CrossRef]
- Rutkowski, J.M.; Boardman, K.C.; Swarz, M.A. Characterisation of lymphangiogenesis in a model of adult skin regeneration. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, 1402–1410. [Google Scholar] [CrossRef]
- Tan, K.W.; Chong, S.Z.; Wong, F.H.; Evrard, M.; Tan, S.M.; Keeble, J.; Kemeny, M.D.; Ng, L.G.; Abastado, J.P.; Angeli, V. Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF-A bioavailability and secreting VEGF-D. Blood 2013, 122, 3666–3677. [Google Scholar] [CrossRef]
- Zheng, S.Q.; Huang, R.Q.; Zhang, Y.J. Role of matrix metalloproteinases (MMP)-2 and -9 and vascular endothelial growth factor C in lymph node metastasis of breast cancer. Zhonghua Bing Li Xue Za Zhi 2010, 39, 240–244. [Google Scholar]
- Elston, C.W.; Ellis, I.O. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 2002, 41, 154–161. [Google Scholar] [CrossRef]
- Peterson, O.W.; Ronnov-Jessen, L.; Howlett, A.R.; Bissel, M.J. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc. Natl. Acad. Sci. USA 1992, 89, 9064–9068. [Google Scholar] [CrossRef]
- Redondo-Munoz, J.; Ugarte-Berzal, E.; Garcia-Marco, J.A.; del Cerro, M.H.; van den Steen, P.E.; Opdenakker, G.; Terol, M.J.; Garcia-Pardo, A. Alpha4Beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex fro gelatinase B/MMP-9 in chronic leukemia but not in normal B cells. Blood 2008, 112, 169–178. [Google Scholar] [CrossRef]
- Brooks, P.C.; Silletti, S.; von Schalscha, T.L.; Friedlander, M.; Cheresh, D. Disruption of angiogenesis by Pex, a non catalytic fragment with integrin binding activity. Cell 1998, 92, 683–693. [Google Scholar]
- Dufour, A.; Sampson, N.S.; Zucker, S.; Cao, J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. J. Cell Physiol. 2008, 217, 643–651. [Google Scholar] [CrossRef]
- Paupert, J.; Mansat-De Mas, V.; Demur, C.; Salles, B.; Muller, C. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with Monocytic features. Cell Cycle 2008, 7, 1047–1053. [Google Scholar] [CrossRef]
- Redondo-Munoz, J.; Ugarte-Berzal, E.; Terol, M.J.; van den Steen, P.E.; Hernandez del Cerro, M.; Roderfeld, M.; Roeb, E.; Opdenakker, G.; Garcia-Marco, J.A.; Garcia-Pardo, A. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain. Cancer Cell 2010, 17, 160–172. [Google Scholar] [CrossRef]
- Hu, X.; Paik, P.K.; Chen, J.; Yarilina, A.; Kockeritz, L.; Lu, T.T.; Woodgett, J.R.; Ivashkiv, L.B. IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 2006, 24, 563–574. [Google Scholar] [CrossRef]
- Rao, J.S.; Bhoopathi, P.; Chetty, C.; Gujrati, M.; Lakka, S.S. MMP-9 short interfering RNA induced senescence resulting in inhibition of medulloblastoma growth via p16 (INK4a) and mitogen-activated protein kinase pathway. Cancer Res. 2007, 67, 4956–4964. [Google Scholar] [CrossRef]
- Bhoopathi., P.; Chetty, C.; Kunigal., S.; Vanamala, S.K.; Rao, J.S.; Lakka, S.S. Blockage of tumour growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of β1-integrin, ERK, and NF-κB. J. Biol. Chem. 2008, 283, 1545–1552. [Google Scholar]
- Wheeler, D.L.; Dunn, E.F.; Harari, P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7, 493–507. [Google Scholar] [CrossRef]
- Frame, M.C.; Patel, H.; Serrels, B.; Lietha, D.; Eck, M.J. The FERM domain: Organizing the structure and function of FAK. Nat. Rev. Mol. Cell. Biol. 2010, 11, 802–814. [Google Scholar] [CrossRef]
- Stuelten, C.H.; DaCosta Byfield, S.; Arany, P.R.; Karpova, T.S.; Stetler-Stevenson, W.G.; Roberts, A.B. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J. Cell Sci. 2005, 118, 2143–2153. [Google Scholar] [CrossRef]
- Mook, O.R.; Frederiks, W.M.; van Noorden, C.J. The role of gelatinases in colorectal cancer progression and metastasis. Biochim. Biophys. Acta 2004, 1705, 69–89. [Google Scholar]
- Jandova, J.; Janda, J.; Sligh, J.E. Changes in mitochondrial DNA alter expression of nuclear encoded genes associated with tumorigenesis. Exp. Cell. Res. 2012, 318, 2215–2225. [Google Scholar] [CrossRef]
- Friedl, P.; Wolf, K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3, 362–374. [Google Scholar] [CrossRef]
- Sabeh, F.; Shimizu-Hirota, R.; Weiss, S.J. Protease-dependent versus -ndependent cancer cell invasion programs: Three-dimensional amoeboid movement revisited. J. Cell Biol. 2009, 185, 11–19. [Google Scholar] [CrossRef]
- Legrand, C.; Gilles, C.; Zahm, J.M.; Polette, M.; Buisson, A.C.; Kaplan, H.; Birembaut, P.; Tournier, J.M. Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodelling. J. Cell Biol. 1999, 146, 517–529. [Google Scholar] [CrossRef]
- Rolli, M.; Fransvea, E.; Pilch, J.; Saven, A.; Felding-Habermann, B. Activated integrin aplphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 9482–9487. [Google Scholar]
- Shibata, K.; Kikkawa, F.; Nawa, A.; Thant, A.A.; Naruse, K.; Mizutani, S.; Hamaguchi, M. Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronectin in ovarian cancer cells. Cancer Res. 1998, 58, 900–903. [Google Scholar]
- Ozanne, B.W.; McGarry, L.; Spence, H.J.; Johnston, I.; Winnie, J.; Meagher, L.; Stapleton, G. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur. J. Cancer 2000, 36, 1640–1648. [Google Scholar] [CrossRef]
- Shin, E.Y.; Ma, E.K.; Kim, C.K.; Kwak, S.J.; Kim, E.G. Src/ERK but not phospholipase D is involved in keratinocyte growth factor-stimulated secretion of matrix metalloproteinase-9 and urokinase-type plasminogen activator in SNU-16 human stomach cancer cells. J. Cancer Res. Clin. Oncol. 2002, 128, 596–602. [Google Scholar] [CrossRef]
- Thomas, G.J.; Poomsawat, S.; Lewis, M.P.; Hart, I.R.; Speight, P.M.; Marshall, J.F. Alpha v beta 6 integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J. Invest. Dermatol. 2001, 11, 898–904. [Google Scholar]
- Thomas, G.J.; Lewis, M.P.; Hart, I.R.; Marshall, J.F.; Speight, P.M. AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int. J. Cancer 2001, 92, 641–650. [Google Scholar] [CrossRef]
- Sil, H.; Sen, T.; Chatterjee, A. Fibronectin-integrin (alpha5beta1) modulates migration and invasion of murine melanoma cell line B16F10 by involving MMP-9. Oncol. Res. 2011, 19, 335–348. [Google Scholar] [CrossRef]
- Mackay, A.R.; Gomez, D.E.; Nason, A.M.; Thorgeirsson, U.P. Sudies on the effects of laminin, E-8 fragment of laminin and synthetic laminin peptides PA22–2 and YIGRS on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression. Lab. Invest. 1994, 70, 800–806. [Google Scholar]
- Kahn, K.M.; Falcone, D.J. Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression. J. Biol. Chem. 1997, 272, 8270–8275. [Google Scholar] [CrossRef]
- Anderson, R.B. Matrix metalloproteinase-2 is involved in the migration and network formation of enteric neural crest-derived cells. Int. J. Dev. Biol. 2010, 54, 63–69. [Google Scholar] [CrossRef]
- Fortier, A.M.; Asselin, E.; Cadrin, M. Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin up-regulation. J. Biol. Chem. 2013, 288, 11555–11571. [Google Scholar] [CrossRef]
- Xu, D.; McKee, C.M.; Cai, Y.; Ding, Y.; Kessler, B.M.; Muschel, R.J. Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1. Cancer Res. 2010, 70, 6988–6998. [Google Scholar] [CrossRef]
- Pal-Ghosh, S.; Blanco, T.; Tadvalkar, G.; Pajoohesh-Ganji, A.; Parthasarathy, A.; Zieske, J.D.; Stepp, M.A. MMP-9 cleavage of the β4 integrin ectodomain leads to recurrent epithelial erosions in mice. J. Cell Sci. 2011, 124, 2666–2675. [Google Scholar] [CrossRef]
- Taddei, M.L.; Parri, M.; Angelucci, A.; Bianchini, F.; Marconi, C.; Giannoni, E.; Raugei, G.; Bologna, M.; Calorini, L.; Chiarugi, P. EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells. Mol. Cancer Res. 2011, 9, 149. [Google Scholar] [CrossRef]
- Wyckoff, J.; Wang, W.; Lin, E.Y.; Wang, Y.; Pixley, F.; Stanley, E.R.; Graf, T.; Pollard, J.W.; Segall, J.; Condeelis, J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64, 7022–7029. [Google Scholar] [CrossRef]
- Gherardi, E.; Birchmeier, W.; Birchmeier, C.; vande Woude, G. Tageting MET in cancer: Rational and progress. Nat. Rev. Cancer 2012, 12, 89–103. [Google Scholar] [CrossRef]
- Wang, M.; Qin, X.; Mudgett, J.S.; Ferguson, T.A.; Senior, R.M.; Welgus, H.G. Matrix metalloproteinase deficiencies affect contact hypersensitivity: Stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response. Proc. Natl. Acad. Sci. USA 1999, 96, 6885–6889. [Google Scholar]
- Creighton, C.; Hanash, S. Expression of matrix metalloproteinase 9 (MMP-9/gelatinase B) in adenocarcinomas strongly correlated with expression of immune response genes. In Silico Biol. 2003, 3, 301–311. [Google Scholar]
- Zhu, X.S.; Shi, W.; An, G.Y.; Zhang, H.M.; Song, Y.G.; Li, Y.B. Matrix metalloproteinase-9 was involved in the immune-modulatory defect of mesenchymal stem cell from chronic myeloid leukemia patients. Chin. Med. J. 2011, 124, 2423. [Google Scholar]
- Bratcher, P.E.; Weathington, N.M.; Nick, H.J.; Jackson, P.L.; Snelgrove, R.J.; Gaggar, A. Gelatinase B/MMP-9 cleaves SP-D and abrogates its innate immune functions in vitro. PLoS One 2012, 7, e41881. [Google Scholar]
- Geiger, T.; Rordorf, C.; Galakatos, N.; Seligmann, B.; Henn, R.; Lazdins, J.; Vosbeck, K. Recombinant human C5a induces transcription but not translation of interleukin-1 beta mRNA in human monocytes. Res. Immunol. 1992, 143, 117–123. [Google Scholar] [CrossRef]
- Wu, G.; Chen, T.; Shahsafaei, A.; Hu, W.; Bronson, R.T.; Shi, G.P.; Halperin, J.A.; Aktas, H.; Qin, X. Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurisms in mice. Circulation 2010, 121, 1338–1346. [Google Scholar] [CrossRef]
- Voskoboinik, I.; Dunstone, M.A.; Baran, K.; Whisstock, J.C.; Trapani, J.A. Perforin: Structure function and role in human immunopathology. Immunol. Rev. 2010, 235, 35–54. [Google Scholar]
- Nishikawa, H.; Sakaguchi, S. Regulatory T cells in tumor immunity. Int. J. Cancer 2010, 127, 759–767. [Google Scholar]
- Wang, J.; Ke, X.Y. The four types of Tregs in malignant lymphomas. J. Hematol. Oncol. 2011, 4, 50. [Google Scholar] [CrossRef]
- Tan, W.; Zhang, W.; Strasner, A.; Grivennikov, S.; Cheng, J.Q.; Hoffman, R.M.; Karin, M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL.RANK signalling. Nature 2011, 470, 548–553. [Google Scholar] [CrossRef]
- Shah, W.; Yan, X.; Jing, L.; Zhou, Y.; Chen, H.; Wang, Y. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell. Mol. Immunol. 2011, 8, 59–66. [Google Scholar]
- Piersma, S.J.; Welters, M.J.; van den Burg, S.H. Tumor-specific regulatory T cells in cancer patients. Hum. Immunol. 2008, 69, 241–249. [Google Scholar] [CrossRef]
- Kim, J.; Yu, W.; Kovalski, K.; Ossowski, L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semi-quantitative PCR-based assay. Cell 1998, 94, 353–362. [Google Scholar] [CrossRef]
- Bekes, E.M.; Schweighofer, B.; Kupriyanova, T.A.; Zajac, E.; Ardi, V.C.; Quigley, J.P.; Deryugina, E.L. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate co-ordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am. J. Pathol. 2011, 179, 1455–1470. [Google Scholar] [CrossRef]
- Cho, K.; Matsuda, Y.; Ueda, J.; Uchida, E.; Naito, Z.; Ishiwata, T. Keratinocyte growth factor induces matrix metalloproteinase-9 expression and correlates with venous invasion in pancreatic cancer. Int. J. Oncol. 2012, 40, 1040–1048. [Google Scholar]
- Li, J.; Sun, R.; Tao, K.; Wang, G. The CCL21/CCR7 pathway plays a key role in human colon cancer metastasis through regulation of matrix metalloproteinase-9. Dig. Liver Dis. 2011, 43, 40–47. [Google Scholar] [CrossRef]
- Sugino, T.; Kusakabe, T.; Hoshi, N.; Yamaguchi, T.; Kawaguchi, T.; Goodison, S.; Sekimata, M.; Homma, Y.; Suzuki, T. An invasion-independent pathway of blood-borne metastasis: A new murine mammary tumor model. Am. J. Pathol. 2002, 160, 1973–1980. [Google Scholar] [CrossRef]
- Mook, O.R.; van Marle, J.; Vreeling-Sindelarova, H.; Jonges, R.; Frederiks, W.M.; van Noorden, C.J. Visualization of early events in tumor formation of eGFP-transfected rat colon cancer cells in liver. Hepatology 2003, 38, 295–304. [Google Scholar]
- Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2, 563–572. [Google Scholar] [CrossRef]
- Rundhaug, J.E. Matrix metalloproteinases and angiogenesis. J. Cell Mol. Med. 2005, 9, 267–285. [Google Scholar] [CrossRef]
- Kopp, H.G.; Ramos, C.A.; Rafii, S. Contribution of endothelial progenitors and proangiogenic haematopoietic cells to vascularization of tumors and ischemic tissue. Curr. Opin. Hematol. 2006, 13, 175–181. [Google Scholar] [CrossRef]
- Kollet, O.; Dar, A.; Shivtiel, S.; Kalinkovich, A.; Lapid, K.; Sztainberg, Y.; Tesio, M.; Samstein, R.M.; Goichberg, P.; Spiegel, A.; et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 2006, 12, 657–664. [Google Scholar] [CrossRef]
- Chen, X.; Su, Y.; Fingleton, B.; Acuff, H.; Matrisian, L.M.; Zent, R.; Pozzi, A. An orthotopic model of lung cancer to analyse primary and metastatic NSCL growth in integrin alpha1-null mice. Clin. Exp. Metastasis 2005, 22, 185–193. [Google Scholar] [CrossRef]
- Kaplan, R.N.; Psaila, B.; Lyden, D. Niche-to-niche migration of bone-marrow-derived cell. Trends Mol. Med. 2007, 13, 72–81. [Google Scholar] [CrossRef]
- Van Kempen, L.C.L.; Coussens, L.M. MMP-9 potentiates pulmonary metastasis formation. Cancer Cell 2002, 2, 251–252. [Google Scholar] [CrossRef]
- Grange, C.; Tapparo, M.; Collino, F.; Vitillo, L.; Damasco, C.; Deregibus, M.C.; Tetta, C.; Bussolati, B.; Camussi, G. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung pre-metastatic niche. Cancer Res. 2011, 71, 5346–5356. [Google Scholar] [CrossRef]
- Van Deventer, H.W.; Palmieri, D.A.; Wu, Q.P.; McCook, E.C.; Serody, J.S. Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2. J. Immunol. 2013, 190, 4861–4867. [Google Scholar] [CrossRef]
- Kucia, M.; Reca, R.; Miekus, K.; Wanzeck, J.; Wojakowski, W.; Janowska-Wieczorek, A.; Ratajczak, J.; Ratajczak, M.Z. Trafficking of normal stem cells and cancer stem cells involve similar mechanisms: Pivotal role for the SDF-1/CXCR4 axis. Stem Cells 2005, 23, 879–894. [Google Scholar] [CrossRef]
- Kaplan, R.N.; Rifil, S.; Lyden, D. Preparing the “soil”: The pre-metastatic niche. Cancer Res. 2006, 66, 11089–11093. [Google Scholar] [CrossRef]
- Mannello, F.; Tonti, G.A.; Bagnara, G.P.; Papa, S. Role and function of matrix metalloproteinases in the differentiation and biological characterisation of mesenchymal stem cells. Stem Cells 2005, 24, 475–481. [Google Scholar]
- Lee, R.; Kermani, P.; Teng, K.K.; Hempstead, B.L. Regulation of cell survival by secreted proneurotrophins. Science 2001, 294, 1945–1948. [Google Scholar] [CrossRef]
- Vaillant, C.; Meissirel, C.; Mutin, M.; Belin, F.; Lund, L.R.; Thomasset, N. MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing cerebellum. Mol. Cell. Neurosci. 2003, 24, 395–408. [Google Scholar] [CrossRef]
- Chintala, S.K.; Zhang, X.; Austin, J.S.; Fini, M.E. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J. Biol. Chem. 2002, 277, 47461–47468. [Google Scholar] [CrossRef]
- Gazzanelli, G.; Luchetti, F.; Burattini, S.; Mannello, F.; Falcieri, E.; Papa, S. Matrix metalloproteinases expression in HL-60 promyelocytic leukaemia cell during apoptosis. Apoptosis 2000, 5, 165–172. [Google Scholar] [CrossRef]
- Moshal., K.S.; Tipparaju, S.M.; Vacek, T.P.; Kumar, M.; Singh, M.; Franke, I.E.; Patibandla, P.K.; Tyagi, N.; Rai, J.; Metreveli, N.; et al. Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H890–H897. [Google Scholar] [CrossRef]
- Kowluru, R.A.; Mohammad, G.; dos Santos, J.M.; Zhong, Q. Abrogation of gelatinase B/MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Diabetes 2011, 60, 3023–3033. [Google Scholar] [CrossRef]
- Overchin, A.V.; Tyagi, N.; Rodriguez, W.E.; Hyden, M.R.; Moshal, K.S.; Tyagi, S.C. Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. J. Appl. Physiol. 2005, 99, 2398–2405. [Google Scholar] [CrossRef]
- Chetty, C.; Lakka, S.S.; Bhoopathi, P.; Gondi, C.S.; Veeravalli, K.K.; Fassett, D.; Klopfenstein, J.D.; Dinh, D.H.; Gujrati, M.; Rao, J.S. Urokinase plasminogen activator and /or matrix metalloproteinase-9 inhibition induces apoptosis signalling through lipid rafts in glioblastoma xenograft cells. Mol. Cancer Ther. 2010, 9, 2605–2617. [Google Scholar] [CrossRef]
- Shchors, K.; Nozawa, H.; Xu, J.; Rostker, F.; Swigart-Brown, L.; Evan, G.; Hanahan, D. Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis. Oncogene 2013, 32, 502–513. [Google Scholar] [CrossRef]
- Deryugina, E.L.; Quigley, J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25, 9–34. [Google Scholar] [CrossRef]
- Acuff, H.B.; Carter, K.J.; Fingleton, B.; Gorden, D.L.; Matrisian, L.M. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in lung microenvironment. Cancer Res. 2006, 66, 259–266. [Google Scholar] [CrossRef]
- Itoh, T.; Tanioka, M.; Matsuda, H.; Nishimoto, H.; Yoshioka, T.; Suzuki, R.; Uehira, M. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastasis 1999, 17, 177–181. [Google Scholar] [CrossRef]
- Pozzi, A.; Moberg, P.E.; Miles, L.A.; Wagner, S.; Soloway, P.; Gardner, H.A. Elevated matrix metalloproteinase and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. USA 2000, 97, 2202–2207. [Google Scholar]
- Pozzi, A.; LeVine, W.F.; Gardner, H.A. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002, 21, 272–281. [Google Scholar] [CrossRef]
- Chen, X.; Su, Y.; Fingleton, B.; Acuff, H.; Matrisian, L.M.; Zent, R.; Pozzi, A. Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells. Int. J. Cancer 2005, 116, 52–61. [Google Scholar] [CrossRef]
- Buck, T.B.; Yoshiji, H.; Harris, S.R.; Bunce, O.R.; Thorgeirsson, U.P. The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinase-1 on the development of breast cancer in mice. Ann. NY Acad. Sci. USA 1999, 878, 732–735. [Google Scholar] [CrossRef]
- De Lornzo, M.S.; Ripoll, G.V.; Yoshiji, H.; Yamazaki, M.; Thorgeirsson, U.P.; Alonso, D.F.; Gomez, D.E. Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinase-1. In Vivo 2003, 17, 45–50. [Google Scholar]
- Yoshiji, H.; Kuriyama, S.; Miyamoto, Y.; Thorgeirsson, U.P.; Gomez, D.E.; Kawata, M.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Tsujinoue, H.; et al. Tissue inhibitor of metalloproteinase-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000, 32, 1248–1254. [Google Scholar] [CrossRef]
- Dziembowska, M.; Wlodarczyk, J. MMP9: Novel function in synaptic plasticity. Int. J. Biochem. Cell Biol. 2012, 44, 709–713. [Google Scholar] [CrossRef]
- Zucker, S.; Cao, J.; Chen, W.-T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2001, 19, 6642–6650. [Google Scholar] [CrossRef]
- Pavlaki, M.; Zucker, S. Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 2003, 22, 177–203. [Google Scholar] [CrossRef]
- Overall, C.M.; Kleifeld, O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006, 6, 227–239. [Google Scholar] [CrossRef]
- McCawley, L.J.; Wright, J.; LaFleur, B.J.; Crawford, H.C.; Matrisian, L.M. Keratinocyte expression of MMP-3 enhances differentiation and prevents tumor establishment. Am. J. Pathol. 2008, 173, 1528–1529. [Google Scholar] [CrossRef]
- McCawley, L.J.; Crawford, H.C.; King, L.E., Jr.; Mudgett, J.; Matrisian, L.M. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res. 2004, 64, 6965–6972. [Google Scholar]
- Kopitz, C.; Gerg, M.; Bandapalli, O.R.; Ister, D.; Pennington, C.J.; Hauser, S.; Flecgsig, C.; Krell, H.W.; Antolovic, D.; Brew, K.; et al. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by inducing hepatocyte growth factor signalling. Cancer Res. 2007, 67, 8615–8623. [Google Scholar] [CrossRef]
- Wolf, K.; Mazo, I.; Leung, H.; Engelke, K.; von Andrian, U.H.; Deryugina, E.L.; Strongin, A.Y.; Brocker, E.B.; Friedl, P. Compensation mechanism in tumor cell migration: Mesenchymal-amoeboid transition after blocking of peri-cellular proteolysis. J. Cell Biol. 2003, 160, 267–277. [Google Scholar] [CrossRef]
- Hu, J.; van den Steen, P.E.; Sang, Q.X.; Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 2007, 6, 480–498. [Google Scholar] [CrossRef]
- Martens, E.; Leyssen, A.; van Aelst, I.; Fiten, P.; Piccard, H.; Hu, J.; Descamps, F.J.; van den Steen, P.E.; Proost, P.; van Damme, J.; et al. A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim. Biophys. Acta 2007, 1770, 178–186. [Google Scholar] [CrossRef]
- Stefanidakis, M.; Karjalainen, K.; Jaalouk, D.E.; Gahmberg, C.G.; O’Brien, S.; Pasqualini, R.; Arap, W.; Koivunen, E. Role of leukemia cell invadosome in extramedullary infiltration. Blood 2009, 114, 3008–3017. [Google Scholar] [CrossRef]
- Suojanen, J.; Vilen, S.-T.; Nyberg, P.; Heikkila, P.; Penate-Medina, O.; Saris, P.E.J.; Hagstrom, J.; Ranta, T.-M.; Salo, T.; Sorsa, T.; et al. Selective gelatinase inhibitor peptide is effective in targeting tongue carcinoma cell tumors in vivo. Anticancer Res. 2011, 31, 3659–3664. [Google Scholar]
- Burg-Roderfeld, M.; Roderfeld, M.; Wagner, S.; Henkel, C.; Grotzinger, J.; Roeb, E. MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int. J. Oncol. 2007, 30, 985–992. [Google Scholar]
- Urgate-Berzal, E.; Bailon, E.; Amigo-Jiminez, I.; Vituri, C.L.; Hernandez del Cerro, M.; Terol, M.J.; Albar, J.P.; Rivas, G.; Barcia-Marco, J.A.; Garcia-Pardo, A. A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic Lymphocytic Leukaemia B cells. J. Biol. Chem. 2012, 287, 27601–27613. [Google Scholar] [CrossRef]
- Bjorklund, M.; Heikkila, P.; Koivunen, E. Peptide inhibition of catalytic and non-catalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J. Biol. Chem. 2004, 279, 29589–29597. [Google Scholar] [CrossRef]
- Vandooren, J.; Geurts, N.; Opdenakker, G. Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain. World J. Biol. Chem. 2011, 26, 14–24. [Google Scholar]
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).